



US012390484B2

(12) **United States Patent**
Xu

(10) **Patent No.:** US 12,390,484 B2
(45) **Date of Patent:** *Aug. 19, 2025

(54) **ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME**

(71) Applicant: **Brii Biosciences, Inc.**, Durham, NC (US)

(72) Inventor: **Lianhong Xu**, Palo Alto, CA (US)

(73) Assignee: **Brii Biosciences, Inc.**, Durham, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **18/467,985**

(22) Filed: **Sep. 15, 2023**

(65) **Prior Publication Data**

US 2024/0245716 A1 Jul. 25, 2024

Related U.S. Application Data

(63) Continuation of application No. 17/583,805, filed on Jan. 25, 2022, now Pat. No. 11,793,827.

(60) Provisional application No. 63/141,450, filed on Jan. 25, 2021.

(51) **Int. Cl.**

C07H 19/16 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/4985 (2006.01)
A61K 31/7076 (2006.01)
A61K 47/10 (2017.01)

(52) **U.S. Cl.**

CPC *A61K 31/7076* (2013.01); *A61K 31/4439* (2013.01); *A61K 31/4985* (2013.01); *A61K 47/10* (2013.01); *C07H 19/16* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,407,191 A	10/1968	Koert et al.
5,880,154 A	3/1999	Boukrinskaia et al.
7,339,053 B2	3/2008	Kohgo et al.
7,625,877 B2	12/2009	Kohgo et al.
8,039,614 B2	10/2011	Kohgo et al.
11,793,827 B2 *	10/2023	Xu A61K 47/10
11,890,297 B2	2/2024	Xu et al.
2005/0215512 A1	9/2005	Kohgo et al.
2018/0002366 A1	1/2018	Girijavallabhan et al.
2018/0099989 A1	4/2018	Ivachchenko et al.
2019/0185508 A1	6/2019	Alexandre et al.
2020/0079814 A1	3/2020	Ivachchenko et al.
2022/0233567 A1	7/2022	Xu
2022/0249532 A1	8/2022	Xu et al.
2022/0288098 A1	9/2022	Xu
2023/0226093 A1	7/2023	Xu

FOREIGN PATENT DOCUMENTS

CN	109053803 A	12/2018
RU	2728829 C1	7/2020
WO	WO-2005025583 A2	3/2005
WO	WO-2007022073 A2	2/2007
WO	WO-2008011406 A2	1/2008
WO	WO-2011058582 A1	5/2011
WO	WO-2015187596 A2	12/2015
WO	WO-2017053216 A2	3/2017
WO	WO-2018022221 A1	2/2018
WO	WO-2020031131 A1	2/2020
WO	WO-2020044257 A1	3/2020
WO	WO-2020178767 A1	9/2020
WO	WO-2021021717 A1	2/2021
WO	WO-2021038509 A1	3/2021
WO	WO-2021050961 A1	3/2021
WO	WO-2022159872 A1	7/2022

OTHER PUBLICATIONS

Belikov, V.G, "Pharmaceutical Chemistry. Chapter 2.6 Relationship between the chemical structure, properties of substances and their effect on the body", MEDpress-inform (2007); pp. 27-29; 14 pages with English translation.

Dyson, G., et al., "Chemistry of Synthetic Drugs", Moscow, MIR, 1964, pp. 12-19; 25 pages with English machine translation.

Extended European Search Report for European Application No. EP20848596.1 dated Sep. 15, 2023, 9 pages.

Final Office Action for U.S. Appl. No. 18/176,204 dated Aug. 30, 2023, 21 pages.

Ghosh et al., "Organic Carbamates in Drug Design and Medical Chemistry," Journal of Medicinal Chemistry, American Chemical Society, Jan. 7, 2015, vol. 58, Issue 7, pp. 2895-2940.

Hayakawa et al., "Potential of 4'-C-substituted nucleosides for the treatment of HIV-1," Antiviral Chemistry & Chemotherapy, 15: 169-187, Aug. 2004.

International Preliminary Report on Patentability for Application No. PCT/US2022/013660, mailed Aug. 3, 2023, 7 pages.

International Preliminary Report on Patentability for International Application No. PCT/US2020/043713, mailed Feb. 10, 2022, 8 Pages.

International Search Report and Written Opinion for Application No. PCT/US2020/043713, mailed Dec. 15, 2020, 10 pages.

International Search Report and Written Opinion for Application No. PCT/US2022/013660, mailed Jun. 14, 2022, 10 pages.

Invitation to Pay Additional Fees for Application No. PCT/US2022/013660, mailed Apr. 6, 2022, 2 pages.

Iyidogan et al., "Current Perspectives on HIV-1 Antiretroviral Drug Resistance," Viruses, Oct. 2014, 6, pp. 4095-4139.

Kageyama, M., et al., "Enantioselective Total Synthesis of the Potent Anti-HIV Nucleoside EFdA", Organic Letters, vol. 13, No. 19, Oct. 7, 2011, pp. 5264-5266.

(Continued)

Primary Examiner — Traviss C McIntosh, III

(74) **Attorney, Agent, or Firm — Cooley LLP**

(57) **ABSTRACT**

Disclosed herein are adenine derivative prodrugs and compositions thereof that can be used for the treatment of HIV infection or RNA virus infection.

(56)

References Cited**OTHER PUBLICATIONS**

- Kümmerer, K., "Pharmaceuticals in the Environment", Annual Review of Environment and Resources (2010); 35: 57-75.
- Mashkovskiy, M.D., "Drugs", Moscow: "Medicine" (1993) Part 1, pp. 8; 3 pages with English Summary.
- Michailidis et al., "4'-Ethylyn-2-fluoro—2'-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms," The Journal of Biological Chemistry, Aug. 2014, vol. 289, No. 35, pp. 24533-24548.
- Non-Final Office Action for U.S. Appl. No. 17/583,805 dated Mar. 16, 2023, 11 pages.
- Non-Final Office Action for U.S. Appl. No. 17/630,403 mailed Aug. 27, 2024, 15 pages.
- Non-Final Office Action for U.S. Appl. No. 18/176,204 dated May 9, 2023, 19 pages.
- Non-Final Office Action for U.S. Appl. No. 18/176,204 dated May 22, 2024, 23 pages.
- Notice of Reasons for Refusal for Japanese Application No. 2022-505447 mailed Sep. 5, 2024, with English translation, 10 pages.
- Office Action and Search report for Chinese Application No. CN20208066036 dated Jul. 6, 2023, 13 pages.
- Office Action and Search Report for Chinese Patent Application No. CN202080066036.3 dated Jan. 26, 2024, with English Translation, 16 pages.
- Office Action and Search report for Russian Application No. RU2022104985 dated Dec. 29, 2023, 29 pages.
- Office Action and Search Report for Singapore Application No. SG11202200159S dated Apr. 2, 2024, 7 pages.
- Office Action for Chinese Application No. CN20208066036 dated May 21, 2024, 6 pages.
- Office Action for Eurasian Application No. 202392087 mailed Jul. 29, 2024, 12 pages.
- Office Action for Indian Application No. IN202217003901 mailed May 13, 2024, 7 pages.
- Office Action for Taiwan Patent Application No. TW20200125342 dated Mar. 7, 2024, 9 pages.
- Ohrui et al., "Syntheses of 4'-C-Ethylyn-β-D-arabino-and 4'-C-Ethylyn-2'-deoxy-β-D-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity," Journal of Medicinal Chemistry, Nov. 2000, 43, pp. 4516-4525.
- Patel et al., "Synthesis of Islatravir Enabled by a Catalytic, Enantioselective Alkylation of a Ketone," Organic Letters, vol. 22, No. 12, Jun. 9, 2020, pp. 4659-4664, <https://doi.org/10.1021/acs.orglett.0c01431>.
- Pauwels, Rudi, "Aspects of successful drug discovery and development", Antiviral Research 71(2-3), Sep. 2006, pp. 77-89.
- PubChem [Internet]. Bethesda (MD): National Library of Medicine (US); National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 6483431, 4'-Ethylyn-2-Fluoro-2'-Deoxyadenosine; [cited Jul. 31, 2024], 34 pages. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/4_-Ethylyn-2-Fluoro-2_-Deoxyadenosine.
- Rautio et al., "Prodrugs: design and clinical applications". Nature reviews Drug discovery. Mar. 2008; 7(3): 255-70.
- Simplicio et al., "Prodrugs for amines". Molecules. Mar. 3, 2008; 13(3): 519-47.
- Singh et al., "Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase," Pharmaceuticals, 12, 62, Jun. 2019, 14 pages.
- Solyev et al., "Synthesis and Anti-HIV Properties of New Carbamate Prodrugs of AZT," Chemical Biology & Drug Design, Dec. 2012, vol. 80, pp. 947-952.
- Stella et al, eds, "Prodrugs: Challenges and Rewards," Part 2, Chapter "Prodrugs of Carboxylic Acids", Springer, 2007, 35 pages.
- Subbaiah et al., "Coupling of an Acyl Migration Prodrug Strategy with Bio-activation to Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir," Journal of Medicinal Chemistry, Apr. 2018, vol. 61, pp. 4176-4188.
- Tatani et al., "Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors". ACS Medicinal Chemistry Letters. Mar. 12, 2015; 6(3): 244-8.
- Third Party Observation for European Application No. 20848596.1, mailed Mar. 4, 2022, 10 pages.
- Tichy et al., "New prodrugs of Adefovir and Cidofovir," Bioorganic & Medicinal Chemistry, vol. 19, Issue 11, Elsevier Science, Apr. 22, 2011, pp. 3527-3539.
- Wanka et al., "The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives". Chemical reviews. May 8, 2013; 113(5): 3516-604.
- Extended European Search Report for European Application No. 22743369.5 mailed Jan. 21, 2025, 15 pages.
- Liu et al., "The many faces of the adamantyl group in drug design". European journal of medicinal chemistry. Jun. 1, 2011;46(6):1949-63.
- Stimac et al., "Adamantane in drug delivery systems and surface recognition". Molecules. Feb. 1, 2017;22(2): 14 pages.
- Office Action and Search Report for Chinese Application No. 202280009277.3 mailed Apr. 14, 2025, with English translation, 20 pages.

* cited by examiner




Figure 1




Figure 2




Figure 3




Figure 4

1

**ADENOSINE DERIVATIVE AND
PHARMACEUTICAL COMPOSITION
COMPRISING THE SAME**

**CROSS REFERENCE TO RELATED
APPLICATION**

This application is a continuation of U.S. Non-provisional application Ser. No. 17/583,805, filed Jan. 25, 2022, which claims the benefit of and priority to U.S. Provisional Application No. 63/141,450, filed Jan. 25, 2021, each of which is incorporated herein by reference in its entirety.

FIELD

The present disclosure is directed to adenosine derivative prodrugs that can inhibit reverse transcriptase. This disclosure is also directed to pharmaceutical compositions comprising an adenosine derivative prodrug that can be used for the treatment of acquired immunodeficiency syndrome (AIDS), HIV-1, HIV-2, multidrug resistant HIV or a combination thereof.

BACKGROUND

Retroviruses such as human immunodeficiency virus (HIV) have been linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). Multiple strains of retrovirus, such as HIV type-1 (HIV-1) and type-2 (HIV-2) are known to be related to the diseases. The HIV retrovirus infected individuals can be initially asymptomatic, but then develop AIDS related complex (ARC) followed by AIDS. Replication of HIV by a host cell requires integration of the viral genome into the DNA of host cells. A key step in the process involves transcription of the viral RNA genome into DNA via an enzyme known as reverse transcriptase (RT).

A reverse transcriptase typically can have multiple enzymatic functions that can act (1) as an RNA-dependent DNA polymerase transcribing a single-stranded DNA copy of the viral RNA (first DNA), (2) as a ribonuclease destroying the original viral RNA and frees the DNA just produced from the original RNA, and (3) as a DNA-dependent DNA polymerase producing a second, complementary DNA strand using the first DNA strand as a template. The two DNA strands then form double-stranded DNA, which is integrated into the genome of the host cells by an integrase enzyme.

A number of compounds can inhibit reverse transcriptase (RT) activity. These compounds can be useful for the treatment of HIV infection in humans by inhibiting HIV replication in infected cells or individuals. Examples of the compounds approved for use in treating HIV infection and AIDS include nucleoside RT inhibitors (NRTI) such as 3'-azido-3'-deoxythymidine (AZT, also known as Zidovudine (ZDV), azidothymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), d4T, 3TC, abacavir, emtricitabine, and tenofovir disoproxil fumarate, as well as non-nucleoside RT inhibitors (NNRTI) such as nevirapine, delavirdine, efavirenz, rilpivirine and doravirine (DHHS guidelines: <https://aidsinfo.nih.gov/understanding-hiv-aids>, Iyidogan & Anderson, Viruses, 6, 4095-4139, 2014, doi: 10.3390/v6104095; Hayakawa et al., Antiviral Chem & Chemotherapy, 15:169-187, 2004; Ohrul et al., J. Med. Chem. 43, 4516-4525, 2000; Pauwels, Antiviral Research, 71, 77-89, 2006.).

2

An adenosine derivative EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine, also known as MK-8591, islatravir) is a NRTI that has been demonstrated to have anti-HIV activity via inhibiting reverse transcriptase by preventing translocation (U.S. Pat. Nos. 7,339,053, 7,625,877, 8,039,614. Singh et al., Pharmaceuticals, 12, 62, 2019, DOI: 10.3390/ph12020062, each of which is incorporated by reference herein in its entirety). This compound has broad inhibitory activity and potency for different subtypes and mutations including HIV-1, HIV-2, and multidrug resistant (MDR) and wildtype (WT) strains, and reverse transcriptase inhibitor (RTI) resistant viruses. Some modified EFdAs and prodrugs have been described in U.S. Patent Publication No.: 2018/0002366, incorporated by reference herein in its entirety.


A common issue that arises from the treatment of HIV infection with anti-retroviral inhibitory compounds is resistance of the viruses to the inhibitors. Such resistance is typically the result of mutations that occur in the reverse transcriptase segment of the pol gene. The continued use of antiviral compounds, such as the inhibitory compounds, to prevent HIV infection will inevitably result in the emergence of new resistant strains of HIV. Therefore, there is a continuing need for new RT inhibitors that are effective against HIV strains including mutant HIV and multidrug-resistant HIV strains.

Another common issue is the medication adherence. Medication adherence is essential for individuals with HIV to have successful therapy over a lifetime. Adherence to a daily regimen can be challenging, which also has negative impact on the patient's quality of life with daily reminders of their HIV status. Accordingly, there is a need to identify long-acting compounds or regimens (for example, once a week, once a month or once every two-month therapy) for patients to overcome these challenges tied to taking daily, oral medication.

SUMMARY

The present disclosure is related to adenosine derivatives and compositions thereof that can be used to treat retroviral diseases such as HIV and AIDS.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)G—;

R¹ is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R² is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R¹ and R² is not H;

R¹ and R² can join together with the atoms to which they are attached to form a 3- to 25-membered heterocyclic ring; and


R³ is selected from the group consisting of H, —(CO)G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ia), (Id), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

R³ is selected from the group consisting of H, —(CO)G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ic), (Id), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Ic)



20

25

30

35

30

35

40

45

50

50

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55

55


55

55

55

55

55



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;


R² is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl;

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ig) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl; and

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ih) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:


G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, —C₂₋₂₀alkynylene-, —C₁₋₂₀haloalkylene-, —C₁₋₂₀alkoxyalkylene-, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R^3 is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ii), (Ij), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(Ii)

5

10


15

20

25

30

(Ij)



35

40


wherein:

D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, and —C₂₋₂₀alkynylene-, —C₁₋₂₀haloalkylene-, —C₁₋₂₀alkoxyalkylene-, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and


R^3 is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ik), (II), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Ik)



(II)



30


(II)

wherein:

R^3 is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Im) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Im)



A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R^3 is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl,

9

C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.


In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (In), (Io), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(In)

5

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ip) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



10

15

wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:


G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Iq), (Ir), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(Io)

35

40

45


50

wherein:

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.



55

60


65

10

11

-continued

(Ir)



12

wherein:

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R^6 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the adenosine derivative is selected from the group consisting of:

Compound No	Structure	Chemical Name
1		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantyl acetate
2		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate
3		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl adamantan-1-carboxylate
4		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantyl carbonate

Compound No	Structure	Chemical Name
5		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 1-adamantyl carbonate
6		(((2R,3S,5R)-3-(((1-adamantyl)oxy)carbonyl)oxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl 1-adamantyl carbonate
7		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 2-(1-adamantyl)ethyl carbonate
8		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate
9		((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyloxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate

15

-continued

16

Compound No	Structure	Chemical Name
10		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate
11		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxy-methyl)tetrahydrofuran-3-yl) 3-(1-adamantyl)propyl carbonate
12		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)-methyl 4-(1-adamantyl)-butyl carbonate
13		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxy-methyl)tetrahydrofuran-3-yl) 4-(1-adamantyl)butyl carbonate
14		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propanoate
15		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butanoate






-continued

Compound No	Structure	Chemical Name
16		(10aR,12R,13aS)-12-(6-amino-2-fluoro-9H-purin-9-yl)-10a-ethynylhexahydro-4H,10H-furo[3,2-d][1,3,7,9]tetraoxacyclododecene-2,8-dione
17		(11aR,13R,14aS)-13-(6-amino-2-fluoro-9H-purin-9-yl)-11a-ethynyloctahydro-11H-furo[3,2-d][1,3,7]trioxacyclotridecene-2,9(4H)-dione
18		((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) ethyl carbonate
19		((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) isobutyrate
20		((2R,3S,5R)-2-((((1-adamantyl)methoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) isobutyrate

-continued

Compound No	Structure	Chemical Name
21		((2R,3S,5R)-2-(((3-(1-adamantyl)propoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) isobutyrate
22		((2R,3S,5R)-3-[3-(1-adamantyl)propanoyloxy]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate
23		((2R,3S,5R)-3-(1-adamantylmethoxycarbonyloxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate
24		((2R,3S,5R)-2-(1-adamantylmethoxycarbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) ethyl carbonate
25		((2R,3S,5R)-2-[4-(1-adamantyl)butoxycarbonyloxymethyl]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) ethyl carbonate

-continued

Compound No	Structure	Chemical Name
26		((2R,3S,5R)-2-[3-(1-adamantyl)propoxycarbonyloxymethyl]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) ethyl carbonate
27		1-adamantyl ((2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-3-ethoxycarbonyloxy-2-ethynyl-tetrahydrofuran-2-yl)methyl carbonate
28		((2R,3S,5R)-2-(1-adamantyloxycarbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) 2-methylpropanoate
29		(1R,13R,15R)-15-(6-amino-2-fluoro-9H-purin-9-yl)-13-ethynyl-2,9,11,14-tetraoxabicyclo[11.3.0]hexadecane-3,10-dione
30		(6R,8R,10R)-8-(6-amino-2-fluoro-9H-purin-9-yl)-10-ethynyl-3,5,9,12,14-pentaoxatricyclo[14.4.0.06,10]icosane-4,13-dione

and a pharmaceutically acceptable salt, tautomer, or solvate thereof.

The present disclosure is further directed to a pharmaceutical composition comprising one or more adenosine derivatives, pharmaceutically acceptable salts, stereoisomers, tautomer, or solvate or a combination thereof disclosed herein, and one or more pharmaceutically acceptable carriers.

The present disclosure is also directed to a process for making compound having formula (I). In one embodiment, the process for making compound having formula (I) is as described in the Examples provided herein.

The present disclosure is also directed to a method for the treatment of a disease (e.g., Acquired Immune Deficiency Syndrome (AIDS) or human immunodeficiency virus (HIV)), the method comprising administering to a subject in need thereof an effective dosage of a pharmaceutical composition comprising one or more of the adenosine derivatives disclosed herein.

The present disclosure is also directed to a method for the prevention of an infection, the method comprising administering to a subject in need thereof an effective dosage of a pharmaceutical composition comprising one or more of the adenosine derivatives disclosed herein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a Plasma Concentration—Time profile of Compound 2 and EFdA after single IM injection of Compound 2 (10 mg/kg) in cynomolgus monkeys.

FIG. 2 shows a Plasma Concentration—Time profile of Compound 7 and EFdA after single IM injection of Compound 7 (10 mg/kg) in cynomolgus monkeys.

FIG. 3 shows a Plasma Concentration—Time profile of Compound 10 and EFdA after single IM injection of Compound 10 (10 mg/kg) in cynomolgus monkeys.

FIG. 4 shows a Plasma Concentration—Time profile of Compound 12 and EFdA after single IM injection of Compound 12 (10 mg/kg) in cynomolgus monkeys.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

DETAILED DESCRIPTION

Following are more detailed descriptions of various concepts related to, and embodiments of, methods and apparatus according to the present disclosure. It should be appreciated that various aspects of the subject matter introduced above and discussed in greater detail below may be implemented in any of numerous ways, as the subject matter is not limited to any particular manner of implementation. Examples of specific implementations and applications are provided primarily for illustrative purposes.

As used herein, the term “alkyl” or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain radical having from one to twenty carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 20 are included. An alkyl comprising up to 12 carbon atoms is a C₁-C₁₂ alkyl, an alkyl comprising up to 10 carbon atoms is a C₁-C₁₀ alkyl, an alkyl comprising up to 6 carbon atoms

is a C₁-C₆ alkyl and an alkyl comprising up to 5 carbon atoms is a C₁-C₅ alkyl. A C₁-C₅ alkyl includes C₅ alkyls, C₄ alkyls, C₃ alkyls, C₂ alkyls and C₁ alkyl (i.e., methyl). A C₁-C₆ alkyl includes all moieties described above for C₁-C₅ alkyls but also includes C₆ alkyls. A C₁-C₁₀ alkyl includes all moieties described above for C₁-C₅ alkyls and C₁-C₆ alkyls, but also includes C₇, C₈, C₉ and C₁₀ alkyls. Similarly, a C₁-C₂₀ alkyl includes all the foregoing moieties, but also includes C₁₁ and C₂₀ alkyls. Non-limiting examples of C₁-C₂₀ alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.

As used herein, the term “alkylene” or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twenty carbon atoms. Non-limiting examples of C₁-C₂₀ alkylene include methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted.

As used herein, the term “alkenyl” or “alkenyl group” refers to a straight or branched hydrocarbon chain radical containing at least one carbon-carbon double bond and having a number of carbon atoms in the specified range, and which is attached to the rest of the molecule by a single bond. For example, “C₂-C₂₀ alkenyl” (or “C₂-C₂₀ alkenyl”) refers to any of alkenyl having 2 to twenty carbon atoms that is linear or branched, or isomers. In another example C₂-C₆ alkenyl can have 1-butene, 2-butene, 3-butene, isobutene, 1-propenyl, 2-propenyl, and ethenyl (or vinyl). Unless stated otherwise specifically in the specification, an alkenyl group can be optionally substituted.

As used herein, the term “alkenylene” or “alkenylene chain” refers to an unsaturated, straight or branched divalent hydrocarbon chain radical having one or more carbon-carbon double bond and from two to twenty carbon atoms. Non-limiting examples of C₂-C₂₀ alkenylene include ethene, propenylene, n-butenylene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.

As used herein, the term “alkynyl” or “alkynyl group” refers to a straight or branched hydrocarbon chain radical containing at least one carbon-carbon triple bond and having a number of carbon atoms in the specified range, and which is attached to the rest of the molecule by a single bond. For example, “C₂-C₂₀ alkynyl” (or “C₂-C₂₀ alkynyl”) refers to any of alkynyl having 2 to 20 carbon atoms that is linear or branched, or isomers. In another example C₂-C₆ alkynyl can have 1-butynyl, 2-butynyl, 3-butynyl, isobutynyl, 1-propynyl, 2-propynyl, and ethynyl. Unless stated otherwise specifically in the specification, an alkynyl group chain can be optionally substituted.

As used herein, the term “alkynylene” or “alkynylene chain” refers to an unsaturated, straight or branched divalent

hydrocarbon chain radical having one or more carbon-carbon triple bond and from two to twenty carbon atoms. Non-limiting examples of C₂-C₂₀ alkynylene include ethynylene, propynylene, n-butynylene, and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted.

As used herein, the term "cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon consisting solely of carbon and hydrogen atoms, which can include fused or bridged ring systems, having from three to twenty-five carbon atoms and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo [2.2.1]heptanyl, and the like. In some embodiments, "cycloalkyl" refers to any monocyclic ring of an alkane having a number of carbon atoms in the specified range. For example, "C₃-C₂₅ cycloalkyl" (or "C₃-C₂₅ cycloalkyl") refers to monocyclic ring of an alkane having 3 to 25 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.

As used herein, the term "heterocycloalkyl", "heterocyclic ring" or "heterocycle" refers to a saturated, or partially saturated 3- to 25-membered ring which consists of two to twenty-four carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and which is attached to the rest of the molecule by a single bond. Unless stated otherwise specifically in the specification, the heterocycloalkyl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl can be optionally oxidized, e.g., to form an N-oxide, sulfoxide, or sulfone and/or the nitrogen atom can be optionally quaternized, e.g., to form a quaternary ammonium cation. Examples of such heterocycloalkyls include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. In some embodiments, "3- to 10-membered heterocycloalkyl" refers to a cycloalkyl comprising one or more heteroatoms, selected from the group consisting of N, O, and S. In some embodiments, "heterocycloalkyl," "heterocyclic ring" or "heterocycle" refers to a 3-10 member ring structure having carbon atoms and one or more heteroatoms selected from N, O, S or a combination thereof as members of the ring structure. Unless stated otherwise specifically in the specification, a heterocycloalkyl group can be optionally substituted and include saturated and/or unsaturated rings.

As used herein, the term "aryl" refers to a hydrocarbon ring system comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring, and which is attached to the rest

of the molecule by a single bond. For purposes of the present disclosure, the aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems. Aryls include, but are not limited to, 5 aryls derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. In some embodiments, "aryl" 10 refers to phenyl or one or more fused cyclic hydrocarbon ring systems in which at least one ring is aromatic. Unless stated otherwise specifically in the specification, the "aryl" can be optionally substituted.

As used herein, the term "heteroaryl" refers to a 5- to 15 20-membered ring system comprising hydrogen atoms, one to nineteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, at least one aromatic ring, and which is attached to the rest of the molecule by a single bond. For purposes of the present disclosure, the heteroaryl can be a monocyclic, bicyclic, 20 tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl can be optionally oxidized, e.g., to form an N-oxide, sulfoxide, or sulfone and/or the nitrogen atom can be optionally quaternized, e.g., to form a quaternary ammonium cation. Non-limiting examples of heteroaryls can include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, 25 pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl triazolyl (i.e., 1,2,3-triazolyl or 1,2,4-triazolyl), tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl (i.e., the 1,2,3-, 1,2,4-, 1,2,5-(furazanyl), or 1,3,4-isomer), oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Suitable 9- and 30 10-membered heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromenyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, tetrahydro uinolinyl, tetrahydroisoquinolinyl, isoindolyl, benzodioxolyl, benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromanyl, isochromanyl, benzothienyl, 35 benzofuranyl, imidazo[1,2-a]pyridinyl, benzotriazolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, 2,3-dihydrobenzofuranyl, and 2,3-dihydrobenzo-1,4-dioxinyl. Unless stated otherwise specifically in the specification, a heteroaryl group 40 can be optionally substituted.

It is understood that, unless expressly stated to the contrary in a particular context, any of the various cyclic rings and ring systems described herein may be attached to the rest of the compound at any ring atom (i.e., any carbon atom or any heteroatom) or may be attached to the rest of the compound at any two ring atoms provided that the attachment is chemically allowed.

As used herein, the term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro (—F), chloro (—Cl), bromo (—Br), and iodo (—I)).

As used herein, the term "substituted" means any of the groups described herein (e.g., alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, heterocyclyl, and/or heteroaryl) 50 wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylam-

ines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. "Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, "substituted" includes any of the above groups in which one or more hydrogen atoms are replaced with $-\text{NR}_g\text{R}_h$, $-\text{NR}_g\text{C}(=\text{O})\text{R}_h$, $-\text{NR}_g\text{C}(=\text{O})\text{NR}_g\text{R}_h$, $-\text{NR}_g\text{C}(=\text{O})\text{OR}_h$, $-\text{NR}_g\text{SO}_2\text{R}_h$, $-\text{OC}(=\text{O})\text{NR}_g\text{R}_h$, $-\text{OR}_g$, $-\text{SR}_g$, $-\text{SOR}_g$, $-\text{SO}_2\text{R}_g$, $-\text{OSO}_2\text{R}_g$, $-\text{SO}_2\text{OR}_g$, $=\text{NSO}_2\text{R}_g$, and $-\text{SO}_2\text{NR}_g\text{R}_h$. "Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced with $-\text{C}(=\text{O})\text{R}_g$, $-\text{C}(=\text{O})\text{OR}_g$, $-\text{C}(=\text{O})\text{NR}_g\text{R}_h$, $-\text{CH}_2\text{SO}_2\text{R}_g$, $-\text{CH}_2\text{SO}_2\text{NR}_g\text{R}_h$. In the foregoing, R_g and R_h are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocycl, N-heterocycl, heterocyclalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. "Substituted" further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocycl, N-heterocycl, heterocyclalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.

As used herein, the term "isomer" refers to a structural isomer, such as a group or an atom positioned at different locations of a molecule; stereoisomer, such as a chiral isomer, enantiomer, diastereomer and cis/trans isomer; a tautomer, such as amino isomer, imino isomer, or a combination thereof. In non-limiting examples, an adenosine derivative of the present disclosure can have an amino isomer, an imino isomer or a combination thereof. In another non-limiting example, in instances where an $-\text{OH}$ substituent is permitted on a heteroaromatic ring and keto-enol tautomerism is possible, it is understood that the substituent might in fact be present, in whole or in part, in the oxo ($=\text{O}$) form. A mixture of isomers can also be suitable. A mixture of isomers can comprise the respective isomers in all ratios. A salt of an isomer can also be suitable. An adenosine derivative of the present disclosure can comprise isomers thereof, one or more salts thereof, one or more solvates including hydrates thereof, solvated salts thereof or a mixture thereof. Absolute stereochemistry or isomer configuration may be determined by X-ray crystallography, by Vibrational Circular Dichroism (VCD) spectroscopy analysis or a combination thereof.

The adenosine derivatives can be identified by names based on the nomenclature recommended by International Union of Pure and Applied Chemistry (IUPAC) or based on nucleosides (Nucleoside-based nomenclature). The adenosine derivatives can also be identified by chemical structure drawings. Unless expressly stated to the contrary in a particular context, the names and the structures may be used interchangeably.

Any of the atoms in a compound disclosed herein may exhibit their natural isotopic abundances, or one or more of

the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present disclosure is meant to include all suitable isotopic variations of the compounds disclosed herein.

The compounds can be administered in the form of pharmaceutically acceptable salts or solvates. The term "pharmaceutically acceptable salt" refers to a salt or a solvate which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient or subject thereof). A mixture of a compound disclosed herein and one or more salts or solvates thereof is also contemplated herein. Illustrative examples of pharmaceutically acceptable salts include, but are not limited to, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrate, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, y-hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

Furthermore, compounds disclosed herein can exist in amorphous form and/or one or more crystalline forms, or a combination thereof.

The term "RNA virus infection" refers to a disease caused by an RNA virus, such as the common cold, influenza, SARS, COVID-19, hepatitis C, hepatitis E, West Nile fever, Ebola virus disease, rabies, polio, and measles.

The term "HIV infection" refers to a disease caused by the human immunodeficiency virus (HIV), such as HIV-1 and HIV-2. In some cases, the HIV infection can be caused by wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, or multidrug resistant HIV. The term "AIDS" refers to acquired immunodeficiency syndrome, which is caused by HIV infection and an advanced form of the disease.

The term "prodrug" refers to a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound described herein. Thus, the term "prodrug" refers to a precursor of a biologically active compound that is pharmaceutically acceptable. A prodrug may be a biologically inactive or substantially inactive compound which can be metabolized in the body, i.e., in vivo, to produce a drug having a desired activity. The term "substantially inactive" means that a prodrug can have about 1% to about 10% of the activity of the corresponding drug or after being metabolized in vivo, percentage based on weight of the prodrug. In some embodiments, the term "substantially inactive" means that a prodrug has less than about 5% of the activity of the corresponding drug or after being metabolized in vivo, percentage based on weight of the prodrug. The doses for a prodrug and its biologically active compound are considered to be dose-equivalent when they are the same molar amount.

The term "anti-HIV agent", "anti-viral agent" or a grammatical variant refers to a compound, a mixture of one or more compounds, a formulation, a chemical agent or a biological agent such as antibody, protein, peptides, nucleotide, other biological compound, or a combination thereof,

that can be directly or indirectly effective in the inhibition of HIV, the treatment or prophylaxis of HIV infection, and/or the treatment, prophylaxis or delay in the onset or progression of AIDS and/or diseases or conditions arising therefrom or associated therewith, an RNA virus infection, or a combination thereof. The anti-HIV agents can comprise HIV antiviral agents, immunomodulators, anti-infectives, vaccines or a combination thereof useful for treating HIV infection or AIDS. Examples of antiviral agents for Treating HIV infection or AIDS include, but are not limited to, under respective trademarks or registered trademarks with respective owners, atazanavir (Reyataz®), darunavir (Prezista®), dolutegravir (Tivicay®), doravirine (MK-1439), efavirenz (EFV, Sustiva®, Stocrin®), cabotegravir, bictegravir, emtricitabine (FTC, Emtriva®), rilpivirine, etravirine (TMC-125), maraviroc (Selzentry®), rilpivirine (Edurant®), tenofovir DF (DF=disoproxil fumarate, TDF, Viread®), tenofovir hexadecyloxypropyl (CMX-157), tenofovir alafenamide fumarate (GS-7340), lenacapavir (GS-6207), MK-8507. Some of the anti-HIV agents shown above can be used in a salt form; for example, atazanavir sulfate, tenofovir alafenamide fumarate or other salts. An anti-HIV agent can have one or more activities such as entry inhibitor (EI), fusion inhibitor (FI); integrase inhibitor (InI); protease inhibitor (PI); nucleoside reverse transcriptase inhibitor (nRTI or NRTI) or non-nucleoside reverse transcriptase inhibitor (nnRTI or NNRTI), capsid inhibitor. An anti-HIV agent can comprise two or more agents disclosed herein. The adenosine derivative of the present disclosure can be an anti-HIV agent along or in combination with other anti-HIV agent or agents.

Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heteroaryl ring described as comprising in a range of from “1 to 4 heteroatoms” means the ring can comprise 1, 2, 3 or 4 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. Thus, for example, a heterocyclic ring described as containing from “1 to 4 heteroatoms” is intended to include as aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, 3 heteroatoms, or 4 heteroatoms. In other examples, C1-C10 alkyl means an alkyl comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 carbon atoms including all sub-ranges. Thus, a C1-C10 alkyl can be a methyl, ethyl, C4 alkyl, C5 alkyl, C6 alkyl, C7 alkyl, C8 alkyl, C9 alkyl and C10 alkyl, linear or branched. A divalent C1-C10 alkyl can be a —CH₂—, —C₂H₄—, —C₃H₆—, —C₄H₈—, —C₅H₁₀—, —C₆H₁₂—, —C₇H₁₇—, —C₈H₁₈—, —C₉H₁₈— or —C₁₀H₂₀—, linear or a branched. Similarly, C2-C10 alkenyl means an alkenyl comprises 2, 3, 4, 5, 6, 7, 8, 9 and 10 carbon atoms, linear or branched, including all sub-ranges. A linear or a branched alkenyl can be suitable. A C3-C10 cycloalkyl means a cycloalkyl comprises 3, 4, 5, 6, 7, 8, 9 and 10 carbon atoms, linear or branched.

Unless otherwise indicated, open terms for example “contain,” “containing,” “include,” “including,” and the like mean comprising.


The singular forms “a”, “an”, and “the” are used herein to include plural references unless the context clearly dictates otherwise. Accordingly, unless the contrary is indicated, the numerical parameters set forth in this application are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure.

The term “about” and its grammatical equivalents in relation to a reference numerical value and its grammatical

equivalents as used herein can include a range of values plus or minus 10% from that value, such as a range of values plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from that value. For example, the amount “about 10” includes amounts from 9 to 11.

The pharmaceutical composition can be suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active ingredient can be coated in a material to protect it from the action of acids and other natural conditions that may inactivate it. The phrase “parenteral administration” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. In some embodiments, the pharmaceutical compositions of the present disclosure are formulated for intramuscular injection and/or subcutaneous injection. Alternatively, the pharmaceutical composition can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, e.g., intranasally, orally, vaginally, rectally, sublingually or topically. The pharmaceutical composition can be in the form of sterile aqueous solutions or dispersions. The pharmaceutical composition can also be formulated in a microemulsion, liposome, or other ordered structure suitable to high drug concentration.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (I) or pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-; R¹ is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R² is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R¹ and R² is not H;

31

R^1 and R^2 can join together with the atoms to which they are attached to form a 3- to 25-membered heterocyclic ring; and

R^3 is selected from the group consisting of H, —(CO)—G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)G-, and —(CO)G-(C₁₋₅alkylene)-J-. In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)G-, and —(CO)G-(C₁₋₅alkylene)-. In some embodiments, A is —(CO)G- or —(CO)G-(C₁₋₅alkylene)-. In some embodiments, A is —(CO)G-(C₁₋₅alkylene)-. In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)O—, and —(CO)O—(C₁₋₅alkylene)-. In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)O—, and —(CO)O—(C₁₋₅alkylene)-. In some embodiments, A is —(CO)O— or —(CO)O—(C₁₋₅alkylene)-. In some embodiments, A is —(CO)O—(C₁₋₅alkylene)-. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.

In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)G-, and —(CO)G-(C₁₋₅alkylene)-J-. In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)G-, and —(CO)G-(C₁₋₅alkylene)-. In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)O—, and —(CO)O—(C₁₋₅alkylene)-. In some embodiments, E is a bond. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.

In some embodiments, R¹ is H, C₁₋₂₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or C₃₋₁₅cycloalkyl. In some embodiments, R¹ is H or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or adamantyl. In some embodiments, R¹ is H or adamantyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantyl.

In some embodiments, R² is H, C₁₋₂₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R² is H, C₁₋₁₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R² is H, C₁₋₁₀alkyl, or C₅₋₁₅cycloalkyl. In some embodiments, R² is H, C₁₋₅alkyl, or C₅₋₁₅cycloalkyl. In some embodiments, R² is H, C₁₋₅alkyl, or adamantyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantyl.


In some embodiments, R¹ and R² can join together with the atoms to which they are attached to form a 6- to 25-membered heterocyclic ring. In some embodiments, R¹ and R² can join together with the atoms to which they are attached to form a 6- to 15-membered heterocyclic ring. In some embodiments, R¹ and R² can join together with the atoms to which they are attached to form a 10- to 15-membered heterocyclic ring. In some embodiments, at least one of R¹ and R² is not H. In some embodiments, R¹ is H, C₁₋₅alkyl, or C₃₋₂₀cycloalkyl and R² is H, C₁₋₅alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or adamantyl and R² is H, C₁₋₅alkyl, or adamantyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or adamantyl and R² is H. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantyl.

32

In some embodiments, R³ is H, —(CO)G-C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, —(CO)C₁₋₅alkyl, —(CO)O-C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, —(CO)CH₃, —(CO)O-CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, R¹ and R² are each as defined herein and R³ is H.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ia), (Ib), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

R¹ is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R² is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R¹ and R² is not H; and

R³ is selected from the group consisting of H, —(CO)G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, R¹ is H, C₁₋₂₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or C₃₋₁₅cycloalkyl. In some embodiments, R¹ is H or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or adamantyl. In some embodiments, R¹ is H or adamantyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantyl.

33

In some embodiments, R² is H, C₁₋₂₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R² is H, C₁₋₁₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R² is H, C₁₋₁₀alkyl, or C₅₋₁₅cycloalkyl. In some embodiments, R² is H, C₁₋₅alkyl, or C₅₋₁₅cycloalkyl. In some embodiments, R² is C₅₋₁₅cycloalkyl. In some embodiments, R² is H, C₁₋₅alkyl, or adamantlyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantlyl.


In some embodiments, R¹ and R² can join together with the atoms to which they are attached to form a 6- to 25-membered heterocyclic ring. In some embodiments, R¹ and R² can join together with the atoms to which they are attached to form a 6- to 15-membered heterocyclic ring. In some embodiments, R¹ and R² can join together with the atoms to which they are attached to form a 10- to 15-membered heterocyclic ring. In some embodiments, at least one of R¹ and R² is not H. In some embodiments, R¹ is H, C₁₋₅alkyl, or C₃₋₂₀cycloalkyl and R² is H, C₁₋₅alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or adamantlyl and R² is H, C₁₋₅alkyl, or adamantlyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or adamantlyl and R² is H. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantlyl.

In some embodiments, R³ is H, —(CO)-G-C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, —(CO)—C₁₋₅alkyl, —(CO)—O—C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, —(CO)—CH₃, —(CO)—O—CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, R¹ and R² are each as defined herein and R³ is H.


In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ic), (Id), or pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Ic)

**34**

-continued

(Id)



20 wherein:

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, and C₁₋₁₀alkyl;

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and


R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, R³ is H, —(CO)-G-C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, —(CO)—C₁₋₅alkyl, —(CO)—O—C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, —(CO)—CH₃, —(CO)—O—CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, C₁₋₅alkoxy, C₂₋₅alkenyl, C₂₋₅alkynyl, C₃₋₆cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl. In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, and C₁₋₅alkoxy. In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₃alkyl, C₁₋₂haloalkyl, and C₁₋₃alkoxy. In some embodiments, R⁴ is H.

In some embodiments, R⁵ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, C₁₋₅alkoxy, C₂₋₅alkenyl, C₂₋₅alkynyl, C₃₋₆cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl. In some embodiments, R⁵ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, and C₁₋₅alkoxy. In some embodiments, R⁵ is selected from the group consisting of H, C₁₋₃alkyl, C₁₋₂haloalkyl, and C₁₋₃alkoxy. In some embodiments, R⁵ is H.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ie), (If), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R² is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl;

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, A is —(CO)-G- or —(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, A is —(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, A is selected from the group consisting of a bond,

—(CO)—, —(CO)-O—, and —(CO)-O—(C₁₋₅alkylene)-J-. In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)-O—, and —(CO)-O—(C₁₋₅alkylene)-J-. In some embodiments, A is —(CO)-O— or —(CO)-O—(C₁₋₅alkylene)-J-. In some embodiments, A is —(CO)-O—(C₁₋₅alkylene)-J-. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.

In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)-O—, and —(CO)-O—(C₁₋₅alkylene)-J-. In some embodiments, E is a bond. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.

In some embodiments, R¹ is H, C₁₋₂₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or C₃₋₁₅cycloalkyl. In some embodiments, R¹ is H or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or adamantlyl. In some embodiments, R¹ is H or adamantlyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantlyl.

In some embodiments, R² is H, C₁₋₂₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R² is H, C₁₋₁₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R² is H, C₁₋₁₀alkyl, or C₅₋₁₅cycloalkyl. In some embodiments, R² is H, C₁₋₅alkyl, or C₅₋₁₅cycloalkyl. In some embodiments, R² is H, C₁₋₅alkyl, or adamantlyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantlyl.

In some embodiments, E is a bond and R¹ is H.


In some embodiments, A is a bond and R² is H.

In some embodiments, R³ is H, —(CO)-G-C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, —(CO)—C₁₋₅alkyl, —(CO)-O—C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, —(CO)—CH₃, —(CO)-O—CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, C₁₋₅alkoxy, C₂₋₅alkenyl, C₂₋₅alkynyl, C₃₋₆cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl. In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, and C₁₋₅alkoxy. In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₃alkyl, C₁₋₂haloalkyl, and C₁₋₃alkoxy. In some embodiments, R⁴ is H.


In some embodiments, R⁵ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, C₁₋₅alkoxy, C₂₋₅alkenyl, C₂₋₅alkynyl, C₃₋₆cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl. In some embodiments, R⁵ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, and C₁₋₅alkoxy. In some embodiments, R⁵ is selected from the group consisting of H, C₁₋₃alkyl, C₁₋₂haloalkyl, and C₁₋₃alkoxy. In some embodiments, R⁵ is H.

In some embodiments, the adenine derivative of formula (Ie) has the structure:




or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein E, R¹, R³, and R⁴ are as defined above.

In some embodiments, the adenosine derivative of formula (Ie) has the structure:




or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein E, R¹, and R³ are as defined above.

In some embodiments, the adenosine derivative of formula (Ie) has the structure:




or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein E, R¹, and R³ are as defined above.

In some embodiments, the adenosine derivative of formula (Ie) has the structure:




or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein E and R¹ are as defined above.

15 In some embodiments, the adenosine derivative of formula (Ie) has the structure:



or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein E and R¹ are as defined above.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ig) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

55 E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

60 J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl; and

R^4 is selected from the group consisting of H, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, E is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G$, and $-(CO)-G-(C_{1-5}\text{alkylene})-J$. In some embodiments, E is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G$, and $-(CO)-G-(C_{1-5}\text{alkylene})$. In some embodiments, E is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-O$, and $-(CO)-O-(C_{1-5}\text{alkylene})$. In some embodiments, E is a bond. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.


In some embodiments, R¹ is H, C₁₋₂₀alkyl, or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or C₃₋₁₅cycloalkyl. In some embodiments, R¹ is H or C₃₋₂₀cycloalkyl. In some embodiments, R¹ is H, C₁₋₅alkyl, or adamantyl. In some embodiments, R¹ is H or adamantyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, the C₃₋₂₀cycloalkyl is adamantyl.

In some embodiments, E is a bond and R¹ is H.

In some embodiments, R³ is H, —(CO)—G—C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, —(CO)—C₁₋₅alkyl, —(CO)—O—C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, —(CO)—CH₃, —(CO)—O—CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, C₁₋₅alkoxy, C₂₋₅alkenyl, C₂₋₅salkynyl, C₃₋₆cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl. In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₅alkyl, C₁₋₅haloalkyl, and C₁₋₅alkoxy. In some embodiments, R⁴ is selected from the group consisting of H, C₁₋₃alkyl, C₁₋₂haloalkyl, and C₁₋₃alkoxy. In some embodiments, R⁴ is H.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ih) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}\text{alkylene})-J-$, $-(CO)-G-(C_{2-10}\text{alkenylene})-J-$, and $-(CO)-G-(C_{2-10}\text{alkynylene})-J-$; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH,
S, —(CO)-G-;

D is selected from the group consisting of $-C_{1-20}alkylene$, $-C_{2-20}alkenylene$, and $-C_{2-20}alkynylene$, $-C_{1-20}haloalkylene$, $-C_{1-20}alkoxyalkylene$, $C_{3-20}cycloalkyl$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R^3 is selected from the group consisting of H, $-(CO)-O-C_{1-10}\text{alkyl}$, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, A is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G$, and $-(CO)-G-(C_{1-5}alkylene)-J$. In some embodiments, A is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G$, and $-(CO)-G-(C_{1-5}alkylene)-$. In some embodiments, A is $-(CO)-G$ or $-(CO)-G-(C_{1-5}alkylene)-$. In some embodiments, A is $-(CO)-G-(C_{1-5}alkylene)-$. In some embodiments, A is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-O$, and $-(CO)-O-(C_{1-5}alkylene)-$. In some embodiments, A is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-O$, and $-(CO)-O-(C_{1-5}alkylene)-$. In some embodiments, A is $-(CO)-O$ or $-(CO)-O-(C_{1-5}alkylene)-$. In some embodiments, A is $-(CO)-O-(C_{1-5}alkylene)-$. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.


In some embodiments, D is a C₁₋₂₀alkylene. In some embodiments, D is a C₁₋₁₀alkylene. In some embodiments, D is a C₃₋₁₀alkylene. In some embodiments, D is a C₃₋₆alkylene.

30 In some embodiments, E is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, and $-(CO)-G-(C_{1-5}\text{alkylene})-J-$. In some embodiments, E is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, and $-(CO)-G-(C_{1-5}\text{alkylene})-$. In some embodiments, E is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-O-$, and $-(CO)-O-(C_{1-5}\text{alkylene})-$. In some embodiments, E is a bond. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.


35

In some embodiments, R^3 is H, $-(CO)-G-C_{1-10}\text{alkyl}$, or $C_{1-10}\text{alkyl}$. In some embodiments, R^3 is H, $-(CO)-C_{1-5}\text{alkyl}$, $-(CO)-O-C_{1-5}\text{alkyl}$, or $C_{1-5}\text{alkyl}$. In some embodiments, the $C_{1-5}\text{alkyl}$ is methyl, ethyl, or isopropyl. In some embodiments, R^3 is H, $-(CO)-CH_3$, $-(CO)-O-CH_3$, or CH_2 . In some embodiments, R^3 is H.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ii), (Ij), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



41
-continued



(Ij)

5
10
15

wherein:


D is selected from the group consisting of $-C_{1-20}$ alkylene-, $-C_{2-20}$ alkenylene-, and $-C_{2-20}$ alkynylene-, $-C_{1-20}$ haloalkylene-, $-C_{1-20}$ alkoxyalkylene-, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R³ is selected from the group consisting of H, $-(CO)-O-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, D is a C_{1-20} alkylene. In some embodiments, D is a C_{1-10} alkylene. In some embodiments, D is a C_{3-10} alkylene. In some embodiments, D is a C_{3-6} alkylene.

In some embodiments, R³ is H, $-(CO)-G-C_{1-10}$ alkyl, or C_{1-10} alkyl. In some embodiments, R³ is H, $-(CO)-C_{1-5}$ alkyl, $-(CO)-O-C_{1-5}$ alkyl, or C_{1-5} alkyl. In some embodiments, the C_{1-5} alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, $-(CO)-CH_3$, $-(CO)-O-CH_3$, or CH_3 . In some embodiments, R³ is H.


In some embodiments, the present disclosure provides an adenine derivative having a structure of formula (Ik), (Il), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(Ik)

50
55
60
65

42
-continued




(II)

wherein:
R³ is selected from the group consisting of H, $-(CO)-O-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, R³ is H, $-(CO)-G-C_{1-10}$ alkyl, or C_{1-10} alkyl. In some embodiments, R³ is H, $-(CO)-C_{1-5}$ alkyl, $-(CO)-O-C_{1-5}$ alkyl, or C_{1-5} alkyl. In some embodiments, the C_{1-5} alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, $-(CO)-CH_3$, $-(CO)-O-CH_3$, or CH_3 . In some embodiments, R³ is H.

In some embodiments, the present disclosure provides an adenine derivative having a structure of formula (Im) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(Im)

wherein:
A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}$ alkylene)-J-, $-(CO)-G-(C_{2-10}$ alkenylene)-J-, and $-(CO)-G-(C_{2-10}$ alkynylene)-J-; wherein:
G is selected from the group consisting of a bond, O, NH, and S;
J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;
R³ is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;
Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and
R⁶ is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.


In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-. In some embodiments, A is —(CO)-G- or —(CO)-G-(C₁₋₅alkylene)-. In some embodiments, A is —(CO)-G-(C₁₋₅alkylene)-. In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)-O—, and —(CO)-O—(C₁₋₅alkylene)-. In some embodiments, A is selected from the group consisting of a bond, —(CO)—, —(CO)-O—, and —(CO)-O—(C₁₋₅alkylene)-. In some embodiments, A is —(CO)-O— or —(CO)-O—(C₁₋₅alkylene)-. In some embodiments, A is —(CO)-O—(C₁₋₅alkylene)-. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.

In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-. In some embodiments, E is selected from the group consisting of a bond, —(CO)—, —(CO)-O—, and —(CO)-O—(C₁₋₅alkylene)-. In some embodiments, E is a bond. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.

In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl. In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, phenyl, or pyridinyl. In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cyclohexyl, piperidinyl, morpholinyl, phenyl, or pyridinyl. In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cyclohexyl, piperidinyl, or morpholinyl. In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is cyclohexyl.

In some embodiments, R³ is H, —(CO)-G-C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, —(CO)—C₁₋₅alkyl, —(CO)-O—C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, —(CO)—CH₃, —(CO)-O—CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (In), (Io), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and

Q⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl. In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, phenyl, or pyridinyl. In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cyclohexyl, piperidinyl, morpholinyl, phenyl, or pyridinyl. In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cyclohexyl, piperidinyl, or morpholinyl. In some embodiments, Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is cyclohexyl.


In some embodiments, R³ is H, —(CO)-G-C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, —(CO)—C₁₋₅alkyl, —(CO)-O—C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, —(CO)—CH₃, —(CO)-O—CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, R⁶ is selected from the group consisting of C₁₋₅alkyl, C₁₋₃haloalkyl, C₁₋₅alkoxy, C₂₋₅salk-

45

enyl, C₂₋₅alkynyl, C₃₋₆cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl. In some embodiments, R⁶ is selected from the group consisting of C₁₋₅alkyl, C₁₋₃haloalkyl, and C₁₋₅alkoxy. In some embodiments, R⁶ is selected from the group consisting of C₁₋₃alkyl, C₁₋₂haloalkyl, and C₁₋₃alkoxy. In some embodiments, R⁶ is methyl, ethyl, isopropyl, methoxy, isopropyl, CF₃, CH₂CF₃, methoxy, ethoxy, or isopropoxy.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Ip) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, -(CO)-, -(CO)-G-, -(CO)-G-(C₁₋₁₀alkylene)-J-, -(CO)-G-(C₂₋₁₀alkenylene)-J-, and -(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, -(CO)-G-;

R³ is selected from the group consisting of H, -(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, A is selected from the group consisting of a bond, -(CO)-, -(CO)-G-, and -(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, A is selected from the group consisting of a bond, -(CO)-, -(CO)-G-, and -(CO)-G-(C₁₋₅alkylene)-. In some embodiments, A is -(CO)-G- or -(CO)-G-(C₁₋₅alkylene)-. In some embodiments, A is -(CO)-G-(C₁₋₅alkylene)-. In some embodiments, A is selected from the group consisting of a bond, -(CO)-, -(CO)-O-, and -(CO)-O-(C₁₋₅alkylene)-. In some embodiments, A is selected from the group consisting of a bond, -(CO)-, -(CO)-O-, and -(CO)-O-(C₁₋₅alkylene)-. In some embodiments, A is -(CO)-O- or -(CO)-O-(C₁₋₅alkylene)-. In some embodiments, A is -(CO)-O- or -(CO)-O-(C₁₋₅alkylene)-. In some embodiments, A is -(CO)-O-(C₁₋₅alkylene)-. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.

In some embodiments, E is selected from the group consisting of a bond, -(CO)-, -(CO)-G-, and -(CO)-G-(C₁₋₅alkylene)-J-. In some embodiments, E is selected from the group consisting of a bond, -(CO)-, -(CO)-G-, and -(CO)-G-(C₁₋₅alkylene)-. In some embodiments, E is


46

selected from the group consisting of a bond, -(CO)-, -(CO)-O-, and -(CO)-O-(C₁₋₅alkylene)-. In some embodiments, E is a bond. In some embodiments, G is a bond or O. In some embodiments, G is O. In some embodiments, J is a bond or O. In some embodiments, J is a bond.

In some embodiments, R³ is H, -(CO)-G-C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, -(CO)-C₁₋₅alkyl, -(CO)-O-C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, -(CO)-CH₃, -(CO)-O-CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, R⁶ is selected from the group consisting of C₁₋₅alkyl, C₁₋₃haloalkyl, C₁₋₅alkoxy, C₂₋₅alkenyl, C₂₋₅alkynyl, C₃₋₆cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl. In some embodiments, R⁶ is selected from the group consisting of C₁₋₅alkyl, C₁₋₃haloalkyl, and C₁₋₅alkoxy. In some embodiments, R⁶ is selected from the group consisting of C₁₋₃alkyl, C₁₋₂haloalkyl, and C₁₋₃alkoxy. In some embodiments, R⁶ is methyl, ethyl, isopropyl, methoxy, isopropyl, CF₃, CH₂CF₃, methoxy, ethoxy, or isopropoxy.

In some embodiments, the present disclosure provides an adenosine derivative having a structure of formula (Iq), (Ir), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

R³ is selected from the group consisting of H, -(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

47

In some embodiments, R³ is H, —(CO)—G—C₁₋₁₀alkyl, or C₁₋₁₀alkyl. In some embodiments, R³ is H, —(CO)—C₁₋₅alkyl, —(CO)—O—C₁₋₅alkyl, or C₁₋₅alkyl. In some embodiments, the C₁₋₅alkyl is methyl, ethyl, or isopropyl. In some embodiments, R³ is H, —(CO)—CH₃, —(CO)—O—CH₃, or CH₃. In some embodiments, R³ is H.

In some embodiments, R⁶ is selected from the group consisting of C₁₋₅alkyl, C₁₋₃haloalkyl, C₁₋₅alkoxy, C₂₋₅alkenyl, C₂₋₅alkynyl, C₃₋₆cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl. In

48

some embodiments, R⁶ is selected from the group consisting of C₁₋₅alkyl, C₁₋₃haloalkyl, and C₁₋₅alkoxy. In some embodiments, R⁶ is selected from the group consisting of C₁₋₃alkyl, C₁₋₂haloalkyl, and C₁₋₃alkoxy. In some embodiments, R⁶ is methyl, ethyl, isopropyl, methoxy, isopropyl, CF₃, CH₂CF₃, methoxy, ethoxy, or isopropoxy.

In some embodiments, the adenosine derivative is a compound of Table 1 or a pharmaceutically acceptable salt, tautomer, or solvate thereof.

TABLE 1

Adenosine compounds of the disclosure.		
Compound No	Structure	Chemical Name
1		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl) acetate
2		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate
3		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl adamantan-1-carboxylate
4		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantyl carbonate

TABLE 1-continued

Compound No	Structure	Chemical Name
5		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 1-adamantyl carbonate
6		(((2R,3S,5R)-3-(((1-adamantyloxy)carbonyloxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl) 1-adamantyl carbonate
7		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-ylmethyl 2-(1-adamantyl)ethyl carbonate
8		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate
9		((2R,3S,5R)-2-(((2-(1-adamantyloxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate

TABLE 1-continued

Adenosine compounds of the disclosure.		
Compound No	Structure	Chemical Name
10		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate
11		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 3-(1-adamantyl)propyl carbonate
12		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butyl carbonate
13		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 4-(1-adamantyl)butyl carbonate
14		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propanoate
15		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butanoate

TABLE 1-continued

Adenosine compounds of the disclosure.		
Compound No	Structure	Chemical Name
16		(10aR,12R,13aS)-12-(6-amino-2-fluoro-9H-purin-9-yl)-10a-ethynylhexahydro-4H,10H-furo[3,2-d][1,3,7,9]tetraoxacyclododecene-2,8-dione
17		(11aR,13R,14aS)-13-(6-amino-2-fluoro-9H-purin-9-yl)-11a-ethynyloctahydro-11H-furo[3,2-d][1,3,7]trioxacyclotridecene-2,9(4H)-dione
18		((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyleoxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrafuran-3-yl) ethyl carbonate
19		((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyleoxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrafuran-3-yl) isobutyrate
20		((2R,3S,5R)-2-(((1-(adamantyl)methoxy)carbonyloxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrafuran-3-yl) isobutyrate

TABLE 1-continued

Compound No	Structure	Chemical Name
21		((2R,3S,5R)-2-(((3-(1-adamantyl)propoxy)-carbonyloxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl)isobutyrate
22		((2R,3S,5R)-3-[3-(1-adamantyl)propoxycarbonyloxy]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate
23		((2R,3S,5R)-3-(1-adamantylmethoxycarbonyloxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate
24		((2R,3S,5R)-2-(1-adamantylmethoxycarbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl)ethyl carbonate
25		((2R,3S,5R)-2-[4-(1-adamantyl)butoxycarbonyloxymethyl]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl)ethyl carbonate

TABLE 1-continued

Adenosine compounds of the disclosure.		
Compound No	Structure	Chemical Name
26		((2R,3S,5R)-2-[3-(1-adamantyl)propoxycarbonyloxymethyl]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl)ethyl carbonate
27		1-adamantyl ((2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-3-ethoxycarbonyloxy-2-ethynyl-tetrahydrofuran-2-yl)methyl carbonate
28		((2R,3S,5R)-2-(1-adamantyloxycarbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) 2-methylpropanoate
29		(1R,13R,15R)-15-(6-amino-2-fluoro-9H-purin-9-yl)-13-ethynyl-2,9,11,14-tetraoxabicyclo[11.3.0]hexadecane-3,10-dione

TABLE 1-continued

Adenosine compounds of the disclosure.		
Compound No	Structure	Chemical Name
30		(6R,8R,10R)-8-(6-amino-2-fluoro-9H-purin-9-yl)-10-ethynyl-3,5,9,12,14-pentaoxatricyclo-[14.4.0.0,6,10]icosane-4,13-dione
20	In some embodiments, the adenosine derivative is selected from the group consisting of:	
25		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate,
30		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl adamantan-1-carboxylate,
35		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantyl carbonate,
40		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 1-adamantyl carbonate,
45		((2R,3S,5R)-3-((((1-adamantyl)oxy)carbonyl)oxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl 1-adamantyl carbonate,
50		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl)ethyl carbonate,
55		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate,
60		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate,
65		((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 3-(1-adamantyl)propyl carbonate,

and a pharmaceutically acceptable salt, tautomer, or solvate thereof.

In some embodiments, the adenosine derivative of formula (I) is selected from the group consisting of:

(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl) acetate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl adamantan-1-carboxylate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 1-adamantyl carbonate,

((2R,3S,5R)-3-((((1-adamantyl)oxy)carbonyl)oxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl 1-adamantyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl)ethyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 3-(1-adamantyl)propyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 4-(1-adamantyl)butyl carbonate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propanoate,

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butanoate,

(10aR,12R,13aS)-12-(6-amino-2-fluoro-9H-purin-9-yl)-10a-ethynylhexahydro-4H,10H-furo[3,2-d][1,3,7,9]tetraoxacyclododecine-2,8-dione,

61

(11aR,13R,14aS)-13-(6-amino-2-fluoro-9H-purin-9-yl)-11a-ethynyloctahydro-11H-furo[3,2-d][1,3,7]trioxacyclotridecene-2,9(4H)-dione,
((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethyltetrahydrofuran-3-yl) ethyl carbonate,
((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethyltetrahydrofuran-3-yl) isobutyrate,
((2R,3S,5R)-2-((((1-adamantyl)methoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethyltetrahydrofuran-3-yl) isobutyrate,
((2R,3S,5R)-2-((((3-(1-adamantyl)propoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethyltetrahydrofuran-3-yl) isobutyrate,
((2R,3S,5R)-3-[3-(1-adamantyl)propoxycarbonyloxy]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate,
((2R,3S,5R)-3-(1-adamantylmethoxycarbonyloxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate,
((2R,3S,5R)-2-(1-adamantylmethoxycarbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) ethyl carbonate,
((2R,3S,5R)-2-[4-(1-adamantyl)butoxycarbonyloxymethyl]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) ethyl carbonate,
((2R,3S,5R)-2-[3-(1-adamantyl)propoxycarbonyloxymethyl]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) ethyl carbonate,
1-adamantyl ((2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-3-ethoxycarbonyloxy-2-ethynyl-tetrahydrofuran-2-yl)methyl carbonate,
((2R,3S,5R)-2-(1-adamantyloxycarbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) 2-methylpropanoate,
(1R,13R,15R)-15-(6-amino-2-fluoro-9H-purin-9-yl)-13-ethynyl-2,9,11,14-tetraoxabicyclo[11.3.0]hexadecane-3,10-dione, and
(6R,8R,10R)-8-(6-amino-2-fluoro-9H-purin-9-yl)-10-ethynyl-3,5,9,12,14-pentaoxatricyclo[14.4.0.0,10]icosane-4,13-dione.

An adenosine derivative of the present disclosure can undergo conversion to a target drug that can comprise reverse transcriptase inhibitor activity in vivo, reverse transcriptase chain terminator activity in vivo, DNA translocation inhibitor activity in vivo, or a combination thereof. Accordingly, the adenosine derivatives of the present disclosure can be used to treat HIV, AIDS, a RNA infection, or other disease disclosed herein.

An adenosine derivative of the present disclosure can be a prodrug that has no or limited activity in its original (i.e., parent) form shown herein and can be metabolized in vivo to exhibit the desired activity of a target drug including a reverse transcriptase inhibitor activity, a reverse transcriptase chain terminator activity, DNA translocation inhibitor activity, or a combination thereof.

Not wishing to be bound by a particular mechanism or theory, Applicants discovered that the adenosine derivatives of the present disclosure can be metabolized in vivo to produce a compound or a mixture of compounds similar to or the same as a target drug 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) that has reverse transcriptase inhibitor and other antiviral activities.


An adenosine derivative of the present disclosure can comprise one or more isomers thereof. In some embodiments, the adenosine derivative of the present disclosure is

62

an isomer of formula (I)—(Ir), or compound (1)-(30). In some embodiments, the isomer is a stereoisomer, e.g., an enantiomer or a diastereomer. In some embodiments, the isomer is an inhibitor of reverse transcriptase having in vivo activity.

The present disclosure is further directed to pharmaceutical compositions comprising an adenosine derivative disclosed herein (e.g., a compound of formula (I)—(Ir) or a compound (1)-(30)) or pharmaceutically acceptable salt, tautomer, or solvate thereof, and a pharmaceutical acceptable carrier.

In some embodiments, the pharmaceutical composition comprises an adenosine derivative having a structure of formula (I) or pharmaceutically acceptable salt, tautomer, or solvate thereof:



35 wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;


R² is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R¹ and R² is not H;

R¹ and R² can join together with the atoms to which they are attached to form a 3- to 25-membered heterocyclic ring; and


R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Ia), (Ib), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

63




(Ia)



(Ib)

64
-continued

(Id)




15

wherein:

20 R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, and C₁₋₁₀alkyl;25 R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and30 R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Ie), (If), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:


(Ie)



50

(If)


(Ic)



55

60

65



wherein:

A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}\text{alkylene})-J-$, $-(CO)-G-(C_{2-10}\text{alkenylene})-J-$, and $-(CO)-G-(C_{2-10}\text{alkynylene})-J-$; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

R¹ is selected from the group consisting of H, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{1-10}\text{alkoxy}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;


R² is selected from the group consisting of H, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{1-10}\text{alkoxy}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, $-(CO)-O-C_{1-10}\text{alkyl}$, and $C_{1-10}\text{alkyl}$;

R⁴ is selected from the group consisting of H, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{1-10}\text{alkoxy}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁵ is selected from the group consisting of H, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{1-10}\text{alkoxy}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Ig) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

E is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}\text{alkylene})-J-$, $-(CO)-G-(C_{2-10}\text{alkenylene})-J-$, and $-(CO)-G-(C_{2-10}\text{alkynylene})-J-$; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

R¹ is selected from the group consisting of H, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{1-10}\text{alkoxy}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, $-(CO)-O-C_{1-10}\text{alkyl}$, and $C_{1-10}\text{alkyl}$; and

R⁴ is selected from the group consisting of H, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{1-10}\text{alkoxy}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Ih) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}\text{alkylene})-J-$, $-(CO)-G-(C_{2-10}\text{alkenylene})-J-$, and $-(CO)-G-(C_{2-10}\text{alkynylene})-J-$; wherein:


G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

D is selected from the group consisting of $-C_{1-20}\text{alkylene}-$, $-C_{2-20}\text{alkenylene}-$, and $-C_{2-20}\text{alkynylene}-$, $-C_{1-20}\text{haloalkylene}-$, $-C_{1-20}\text{alkoxyalkylene}-$, $C_{3-20}\text{cycloalkyl}$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and


R³ is selected from the group consisting of H, $-(CO)-O-C_{1-10}\text{alkyl}$, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Ii), (Ij), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



67

-continued




wherein:


D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, and —C₂₋₂₀alkynylene-, —C₁₋₂₀haloalkylene-, —C₁₋₂₀alkoxyalkylene-, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Ik), (II), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(Ik)



(II)


wherein:

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alk-

65

68enyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Im) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:


A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.


In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (In), (Io), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(In)


69

-continued



R³ is selected from the group consisting of H, —(CO)—G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; 20
 Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and 25
 R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Ip) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:


G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-; R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

70

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative having a structure of formula (Iq), (Ir), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

R³ is selected from the group consisting of H, —(CO)—G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments, the pharmaceutical composition of the present disclosure comprises an adenosine derivative selected from the group consisting of compound as disclosed in Table 1 and a pharmaceutically acceptable salt, tautomer, or solvate thereof.

An adenosine derivative of the present disclosure can comprise one or more isomers thereof. In some embodiments, the adenosine derivative of the present disclosure is an isomer of formula (I)—(Ir), or compound (1)-(30). In some embodiments, the isomer is a stereoisomer, e.g., an enantiomer or a diastereomer. In some embodiments, the isomer is an inhibitor of reverse transcriptase having in vivo activity.

As disclosed above, a pharmaceutical composition of the present disclosure comprises an adenosine derivative that can be free from monophosphate group, diphosphate group, tri-phosphate group or a combination thereof. In some embodiments, an R¹ and/or R² group of an adenosine derivative of disclosed herein is free from monophosphate group, diphosphate group, tri-phosphate group or a combination thereof.

As described, the pharmaceutical composition of the present disclosure comprises a pharmaceutically acceptable carrier.

Non-limiting examples of a pharmaceutically acceptable carrier include a pharmaceutical excipients surfactant, emulsifier, filler, carrier, isotonicifier, dispersing agent, viscosity modifier, resuspending agent, buffer or a combination thereof. Pharmaceutical excipients typically do not have properties of a medicinal or drug active ingredient, also known as active pharmaceutical ingredient (API) and are typically used to streamline the manufacture process or packaging of the active ingredients, or to deliver an API to a patient or other subject. Pharmaceutical acceptable carrier, excipients or inactive ingredients from the Inactive Ingredients Database available from US FDA (<https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download>) can be suitable. Some of Generally Recognized As Safe (GRAS) food substances available form US FDA's GRAS Substances (SCOGS) Database (<https://www.fda.gov/food/generally-recognized-safe-gras/gras-substances-scogs-database>) can also be suitable.

In some embodiments of the present disclosure, the pharmaceutical acceptable carrier comprises polyethylene glycol (PEG), sulfobutylether β -cyclodextrin (SRBCD), acacia, animal oils, benzyl alcohol, benzyl benzoate, calcium stearate, carbomers, cetostearyl alcohol, cetyl alcohol, cholesterol, cyclodextrins, dextrose, diethanolamine, emulsifying wax, ethylene glycol palmitostearate, glycerin, glycerin monostearate, glycerol stearate, glyceryl monooleate, glyceryl monostearate, hydrous, histidine, hydrochloric acid, hydroxpropyl cellulose, hydroxypropyl- β -cyclodextrin (HPBCD), hypromellose (hydroxypropyl methylcellulose (HPMC)), lanolin, lanolin alcohols, lecithin, medium-chain triglycerides, metallic soaps, methylcellulose, mineral oil, monobasic sodium phosphate, monoethanolamine, oleic acid, polyethylene glycols (PEG 3350, PEG 4000, PEG 6000), polyoxyethylene-polyoxypropylene copolymer (poloxamer), polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polysorbate, polyoxyethylene (20) sorbitan monolaurate (Tween 20, Polysorbate 20), polyoxyethylene (20) sorbitan monooleate (Tween 80, Polysorbate 80), povidone, propylene glycol alginate, saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium hydroxide, sodium lauryl sulfate, sodium phosphate monobasic, sodium phosphate dibasic, sorbitan esters, stearic acid, stearyl alcohol, sunflower oil, tragacanth, triethanolamine, vegetable oils, water, xanthan gum, or combinations thereof.

In further embodiments, the pharmaceutical acceptable carrier comprises dextrose, glycerin, histidine, hydrochloric acid, hydroxpropyl cellulose, hydroxypropyl- β -cyclodextrin (HPBCD), hypromellose (hydroxypropyl methylcellulose (HPMC)), polyoxyethylene (20) sorbitan monolaurate (Tween 20, Polysorbate 20), polyethylene glycols (PEG 400, PEG 3350, PEG 4000, PEG 6000), polyoxyethylene-polyoxypropylene copolymer (Poloxamer 188, Poloxamer 407), polyoxyethylene (20) sorbitan monooleate (Tween 80, Polysorbate 80), saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium lauryl sulfate, sodium phosphate monobasic, sodium phosphate dibasic, or a combination thereof.

The pharmaceutical compositions of the present disclosure can further comprise an effective dosage of one or more additional anti-HIV agents (also referred to as anti-viral agents) selected from the group consisting of lenacapavir, atazanavir, atazanavir sulfate, bictegravir, cabotegravir,

darunavir, dolutegravir, doravirine, efavirenz, tenofovir disoproxil fumarate, tenofovir alafenamide, etravirine, a combination of darunavir and cobicistat, rilpivirine, or a combination thereof. In some embodiments, the one or more additional anti-HIV agents are selected from the group consisting of lenacapavir, bictegravir and cabotegravir. In some embodiments, the pharmaceutical compositions of the present disclosure further comprise an effective dosage of one additional anti-HIV agent. In some embodiments, the pharmaceutical compositions of the present disclosure further comprise an effective dosage of two additional anti-HIV agents.


In some embodiments, the pharmaceutical compositions of the present disclosure comprise an adenosine derivative, e.g., a compound of formula (I)—(Ir), or compound (1)-(30), and the one or more additional anti-HIV agents in a single formulation that can be administered to a subject together.

Accordingly, in some embodiments, the pharmaceutical compositions of the present disclosure comprise (1) an effective dosage of: (a) an adenosine derivative or pharmaceutically acceptable salt, tautomer, or solvate thereof (e.g., a compound of formula (I)—(Ir), or compound (1)-(30)); and (b) one or more additional anti-HIV agents disclosed herein; and (2) a pharmaceutically acceptable carrier disclosed herein.

The pharmaceutical composition of the present disclosure can comprise the adenosine derivative and the one or more additional anti-HIV agents in separate formulations that can be administered to a subject simultaneously or sequentially. The pharmaceutical composition of the present disclosure can also be mixed together with one or more additional disclosed anti-HIV agents in separate formulations that can be administered to a subject simultaneously.

The present disclosure is further directed to a method for treating a disease, the method comprising administering a subject in need thereof an effective dosage of a pharmaceutical composition comprising an adenosine derivative (e.g., a compound of formula (I)—(Ir) or compound (1)-(30)) or pharmaceutically acceptable salt, tautomer, or solvate thereof disclosed herein.

In some embodiments of the present methods, the adenosine derivative is a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof.



A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}\text{alkylene})-J-$, $-(CO)-G-(C_{2-10}\text{alkenylene})-J-$, and $-(CO)-G-(C_{2-10}\text{alkynylene})-J-$; wherein:
G is selected from the group consisting of a bond, O, NH, and S;
J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

73


R^1 is selected from the group consisting of H, C_{1-20} alkyl, C_{1-20} haloalkyl, C_{1-20} alkoxy, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R^2 is selected from the group consisting of H, C_{1-20} alkyl, C_{1-20} haloalkyl, C_{1-20} alkoxy, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R^1 and R^2 is not H;

R^1 and R^2 can join together with the atoms to which they are attached to form a 3- to 25-membered heterocyclic ring; and

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is a compound of formula (Ia), (Ib), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:





R^1 is selected from the group consisting of H, C_{1-20} alkyl, C_{1-20} haloalkyl, C_{1-20} alkoxy, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R^2 is selected from the group consisting of H, C_{1-20} alkyl, C_{1-20} haloalkyl, C_{1-20} alkoxy, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R^1 and R^2 is not H; and

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

74

In some embodiments of the present method, the adenosine derivative is a compound of formula (Ic), (Id), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:




wherein:

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, and C_{1-10} alkyl;

R^4 is selected from the group consisting of H, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R^5 is selected from the group consisting of H, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is a compound of formula (Ie), (If), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;


R² is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl;

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenine derivative is a compound of formula (Ig) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl; and

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenine derivative is a compound of formula (Ih) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, and —C₂₋₂₀alkynylene-, —C₁₋₂₀haloalkylene-, —C₁₋₂₀alkoxy-

kylene-, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R^3 is selected from the group consisting of H, $-(CO)-O-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is a compound of formula (Ii), (Ij), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



15

20

25

30

35

40


45

50

55

60

65



15

20

25

30

35

40

45

50

55


60

65

wherein:

R^3 is selected from the group consisting of H, $-(CO)-O-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is a compound of formula (Im) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



40


45

50

55

60

65



wherein:

A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}$ alkylene)-J-, $-(CO)-G-(C_{2-10}$ alkenylene)-J-, and $-(CO)-G-(C_{2-10}$ alkynylene)-J-; wherein: G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl,

wherein:

D is selected from the group consisting of $-C_{1-20}$ alkylene-, $-C_{2-20}$ alkenylene-, and $-C_{2-20}$ alkynylene-, $-C_{1-20}$ haloalkylene-, $-C_{1-20}$ alkoxyalkylene-, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R^3 is selected from the group consisting of H, $-(CO)-O-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is a compound of formula (Ik), (Il), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



79

C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

Q^1 , Q^2 , Q^3 , Q^4 , and Q^5 form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and

R^6 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is a compound of formula (In), (Io), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



50

wherein:

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;


Q^1 , Q^2 , Q^3 , Q^4 , and Q^5 form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and

R^6 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is a compound of formula (Ip) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

80

(Ip)



wherein:

A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}$ alkylene)-J-, $-(CO)-G-(C_{2-10}$ alkenylene)-J-, and $-(CO)-G-(C_{2-10}$ alkynylene)-J-; wherein:


G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and


R^6 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is a compound of formula (Iq), (Ir), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



81

-continued



wherein:

R^3 is selected from the group consisting of H, $-(CO-$
 $G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl,
 C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and


R^6 is selected from the group consisting of C_{1-10} alkyl,
 C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl,
 C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

In some embodiments of the present method, the adenosine derivative is selected from the group consisting of compound as disclosed in Table 1 and a pharmaceutically acceptable salt, tautomer, or solvate thereof.

An adenosine derivative of the present disclosure can comprise one or more isomers thereof. In some embodiments, the adenosine derivative of the present disclosure is an isomer of formula (I)—(Ir), or compound (1)-(30). In some embodiments, the isomer is a stereoisomer, e.g., an enantiomer or a diastereomer. In some embodiments, the isomer is an inhibitor of reverse transcriptase having in vivo activity.


In some embodiments of the present methods, the pharmaceutical composition is administered to a subject via intramuscular (IM) injection, subcutaneous (SC) injection, intravenous (IV) injection, oral administration, topical application, implant application or a combination thereof. In some embodiments, the pharmaceutical compositions of the present disclosure are formulated for intramuscular injection and/or subcutaneous injection. An implant application can include an implantable device or a film that contains the pharmaceutical composition disclosed herein. The implant application can comprise vaginal ring, film, membrane, patch, other devices, or a combination thereof.

The method of the present disclosure can further comprise measuring a specimen of the subject to determine a measured level of a target drug in the specimen, wherein the target drug can have a formula (T-1):

**82**

an isomer thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, X is a halogen selected from the group consisting of F, Cl, Br and I. In some embodiments X is I.

5 In some embodiments, the target drug is a compound having a structure of formula (T-1A):



or a pharmaceutically acceptable salt, stereoisomer, tautomer thereof. Formula (T-1A) is also referred to herein as EFdA.

In some embodiments, the target drug is (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (also referred to as 4'-ethynyl-2-fluoro-2'-deoxyadenosine, EFdA), or a pharmaceutically acceptable salt thereof.

In some embodiments, the target drug is a degradation or 30 metabolized product of the compound (T-1), (T-1A) or EFdA.

The specimen can be a blood sample, a urine sample, a body fluid sample, a tissue sample or a combination thereof from the subject, such as a patient.

35 The measured level of the target drug can be determined with an analytical method known to those skilled in the art, such as, but not limited to, HPLC, GC, MS, GC-MS, or a combination thereof.

The method of the present disclosure can further comprise 40 adjusting the effective dosage to produce a modified effective dosage if the measured level of the target drug is different from a predetermined target level of the target drug and administering the modified effective dosage to the subject.

45 In some embodiments of the present method, the disease is HIV, Acquired Immune Deficiency Syndrome (AIDS), or an RNA virus infection. In some embodiments, the disease is AIDS, wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, multidrug resistant HIV, or an RNA virus infection. In some 50 embodiments, the disease is wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, or multidrug resistant HIV.

In some embodiments, the methods of the present disclosure 55 further comprise administering to a subject an effective dosage of one or more additional anti-HIV agents selected from lenacapavir, atazanavir, atazanavir sulfate, bictegravir, cabotegravir, darunavir, dolutegravir, doravirine, efavirenz, tenofovir disoproxil fumarate, tenofovir alafenamide, etravirine, a combination of darunavir and cobicistat, rilpivirine, MK-8507 or a combination thereof. In some embodiments, the one or more additional anti-HIV agents are selected from the group consisting of lenacapavir, bictegravir and cabotegravir. Other anti-HIV agents identified or developed, or 60 combination thereof, can also be suitable.

Combinations of the adenosine derivative of the present disclosure (e.g., formula (I)—(Ir) or compound (1)-(30) and

83

the one or more additional anti-HIV agents described herein can be useful for the treatment or prophylaxis of AIDS or other HIV related symptoms. The additional anti-HIV agents can be employed in these combinations in their conventional dosage ranges and regimens as reported in the art, including, for example, the dosages described in the Physicians' Desk Reference, Thomson PDR, Thomson PDR, 57th edition (2003), the 58th edition (2004), or the 59th edition (2005) and the current Physicians' Desk Reference (68th ed.). (2014), Montvale, N.J.: PDR Network.

An adenosine derivative of the present disclosure and the one or more additional anti-HIV agents described herein can be administered to a subject together or separately via oral administration, parenteral administration or a combination thereof. In some embodiments, parenteral administration comprises SC and/or IM injection. The adenosine derivative and the one or more additional anti-HIV agents can be administered to the subject with a daily, weekly, biweekly or monthly administration schedule.

The present disclosure is further directed to a use of the pharmaceutical composition for the treatment of a disease in a subject in need thereof, wherein the disease is Acquired Immune Deficiency Syndrome (AIDS), wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, multidrug resistant HIV, or an RNA virus infection. Any of the aforementioned pharmaceutical compositions can be suitable. The pharmaceutical composition can be used together with one or more additional anti-HIV agents for the treatment of the disease mentioned herein. The adenosine derivative and the one or more additional anti-HIV agents can be administered to a subject together or separately via oral administration, parenteral administration or a combination thereof. The adenosine derivative and the one or more additional anti-HIV agents can be administered to the subject with a daily, weekly, biweekly or monthly administration schedule.

The present disclosure is further directed to a use of the adenosine derivative, optionally, one or more pharmaceutically acceptable carriers, disclosed herein for manufacturing a medicament for treating a disease, wherein the disease is Acquired Immune Deficiency Syndrome (AIDS), wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, multidrug resistant HIV, or an RNA virus infection. Aforementioned adenosine derivatives can be suitable. Aforementioned pharmaceutically acceptable carriers can be suitable.

The present disclosure is further directed to a method for the prevention of infection in a subject in need thereof, the method comprising administering the subject an effective dosage of a pharmaceutical composition of the present method disclosed herein, wherein the subject is free from detectable symptoms of the infection. In some embodiments, the infection comprises a disease selected from Acquired Immune Deficiency Syndrome (AIDS), an infection of wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, multidrug resistant HIV, an RNA virus infection, or a combination thereof.

The detectable symptoms include, but are not limited to, symptoms of Acquired Immune Deficiency Syndrome (AIDS), symptoms of infection of HIV viruses comprising wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, multidrug resistant HIV, or a combination thereof. The detection of the HIV viruses can be done by PCR, reverse PCR, immunodetection of an antigen or an antibody related to AIDS or HIV.

84

In some embodiments, the pharmaceutical composition of the present method is administered to said subject with a daily, weekly, biweekly or monthly administration schedule.

In some embodiments, the method of the present disclosure further comprises administering the subject an effective dosage of one or more additional anti-HIV agents selected from lenacapavir, atazanavir, atazanavir sulfate, bictegravir, cabotegravir, darunavir, dolutegravir, doravirine, efavirenz, tenofovir disoproxil fumarate, tenofovir alafenamide, etravirine, a combination of darunavir and cobicistat, rilpivirine, MK-8507 or a combination thereof. In some embodiments, the one or more additional anti-HIV agents are selected from the group consisting of lenacapavir, bictegravir and cabotegravir.


The one or more additional anti-HIV agents can be administered to the subject together with the pharmaceutical composition of the present disclosure or separately.

Without being bound by any particular theory, an advantage of the adenosine derivatives disclosed herein (e.g., formula (I)—(Ir), or compound (1)–(30) is the fast conversion to the target drug. In some embodiments, the fast conversion is a time period of less than about 1 h, e.g., a period of from about 30 min to about 45 min. As described below, greater than about 60% of the adenosine derivatives of the present disclosure surprisingly and unexpectedly can be converted to the target drug within about 30 min in contact with human plasma. In some embodiments, greater than about 60%, greater than about 65%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, or greater than about 95% of an adenosine derivative disclosed herein is converted to the target drug without about 30 min in contact with human plasma. In some embodiments, the conversion occurs *in vitro*. In some embodiments, the conversion occurs *in vivo*. In some embodiments, the conversion occurs after parenteral (e.g. SC and/or IM) administration. In some embodiments, the conversion occurs after oral administration.

NUMBERED EMBODIMENTS OF THE DISCLOSURE

Other subject matter contemplated by the present disclosure is set out in the following numbered embodiments:

1. An adenosine derivative having a structure of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-,

85

$-(CO)-G-(C_{1-10}\text{alkylene})-J-$, $-(CO)-G-(C_{2-10}\text{alkylene})-J-$, and $-(CO)-G-(C_{2-10}\text{alkynylene})-J-$; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

R^1 is selected from the group consisting of H, $C_{1-20}\text{alkyl}$, $C_{1-20}\text{haloalkyl}$, $C_{1-20}\text{alkoxy}$, $C_{2-20}\text{alkenyl}$, $C_{2-20}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R^2 is selected from the group consisting of H, $C_{1-20}\text{alkyl}$, $C_{1-20}\text{haloalkyl}$, $C_{1-20}\text{alkoxy}$, $C_{2-20}\text{alkenyl}$, $C_{2-20}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R^1 and R^2 is not H;

R^1 and R^2 can join together with the atoms to which they are attached to form a 3- to 25-membered heterocyclic ring; and R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}\text{alkyl}$, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$,

$C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

1a. The adenosine derivative of embodiment 1, wherein A is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, and $-(CO)-G-(C_{1-5}\text{alkylene})-J-$.

1b. The adenosine derivative of embodiment 1 or 1a, wherein A is $-(CO)-G-$ or $-(CO)-G-(C_{1-5}\text{alkylene})-J-$.

1c. The adenosine derivative of any one of embodiments 1-1b, wherein E is a bond, $-(CO)-G-$, and $-(CO)-G-(C_{1-5}\text{alkylene})-J-$.


1d. The adenosine derivative of any one of embodiments 1-1c, wherein E is a bond.

1e. The adenosine derivative of any one of embodiments 1-1d, wherein G is a bond or O.

1f. The adenosine derivative of any one of embodiments 1-1e, wherein J is a bond or O.

1g. The adenosine derivative of any one of embodiments 1-1f, wherein G is O and J is a bond.


1h. The adenosine derivative of any one of embodiments 1-1g, wherein R^1 is H, $C_{1-5}\text{alkyl}$, or adamantly



1i. The adenosine derivative of any one of embodiments 1-1h, wherein R^1 is H.

1j. The adenosine derivative of any one of embodiments 1-1i, wherein R^2 is H, $C_{1-5}\text{alkyl}$, or adamantly.

1k. The adenosine derivative of any one of embodiments 1-1j, wherein R^2 is adamantly





86

11. The adenosine derivative of any one of embodiments 1-1g, wherein R^1 and R^2 taken together with the atoms to which they are attached form a 6- to 15-membered heterocyclic ring.

1m. The adenosine derivative of any one of embodiments 1-11, wherein R^3 is $-(CO)-C_{1-5}\text{alkyl}$, $-(CO)-O-C_{1-5}\text{alkyl}$, or $C_{1-5}\text{alkyl}$.

1n. The adenosine derivative of any one of embodiments 1-1m, wherein R^3 is H.

2. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Ia), (Ib), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:





wherein:

R^1 is selected from the group consisting of H, $C_{1-20}\text{alkyl}$, $C_{1-20}\text{haloalkyl}$, $C_{1-20}\text{alkoxy}$, $C_{2-20}\text{alkenyl}$, $C_{2-20}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, $C_{3-20}\text{heterocycloalkyl}$, aryl, and heteroaryl;

R^2 is selected from the group consisting of H, $C_{1-20}\text{alkyl}$, $C_{1-20}\text{haloalkyl}$, $C_{1-20}\text{alkoxy}$, $C_{2-20}\text{alkenyl}$, $C_{2-20}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, $C_{3-20}\text{heterocycloalkyl}$, aryl, and heteroaryl, wherein at least one of R^1 and R^2 is not H; and

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}\text{alkyl}$, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, $C_{3-12}\text{heterocycloalkyl}$, aryl, and heteroaryl.

3. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Ic), (Id), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:


R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}alkyl$, and $C_{1-10}alkyl$;

R^4 is selected from the group consisting of H, $C_{1-10}alkyl$, $C_{1-10}haloalkyl$, $C_{1-10}alkoxy$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{3-12}cycloalkyl$, $C_{3-12}heterocycloalkyl$, aryl, and heteroaryl; and

R^5 is selected from the group consisting of H, $C_{1-10}alkyl$, $C_{1-10}haloalkyl$, $C_{1-10}alkoxy$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{3-12}cycloalkyl$, $C_{3-12}heterocycloalkyl$, aryl, and heteroaryl.

4. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Ie), (If), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

50



wherein:
 A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}alkylene)-J-$, $-(CO)-G-(C_{2-10}alkenylene)-J-$, and $-(CO)-G-(C_{2-10}alkynylene)-J-$; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

R^1 is selected from the group consisting of H, $C_{1-10}alkyl$, $C_{1-10}haloalkyl$, $C_{1-10}alkoxy$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{3-20}cycloalkyl$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R^2 is selected from the group consisting of H, $C_{1-10}alkyl$, $C_{1-10}haloalkyl$, $C_{1-10}alkoxy$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{3-20}cycloalkyl$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R^3 is selected from the group consisting of H, $-(CO)-O-C_{1-10}alkyl$, and $C_{1-10}alkyl$; and

R^4 is selected from the group consisting of H, $C_{1-10}alkyl$, $C_{1-10}haloalkyl$, $C_{1-10}alkoxy$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{3-12}cycloalkyl$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R^5 is selected from the group consisting of H, $C_{1-10}alkyl$, $C_{1-10}haloalkyl$, $C_{1-10}alkoxy$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{3-12}cycloalkyl$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

5. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Ig) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815

89

wherein:

E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, C₃₋₂₀heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl; and

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, C₃₋₁₂heterocycloalkyl, aryl, and heteroaryl.

6. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Ih) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;



J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, and —C₂₋₂₀alkynylene-, —C₁₋₂₀haloalkylene-, —C₁₋₂₀alkoxyalkylene-, C₃₋₂₀cycloalkyl, C₃₋₂₀heterocycloalkyl, aryl, and heteroaryl; and

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl.

7. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Ii), (Ij), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

90




wherein:

D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, and —C₂₋₂₀alkynylene-, —C₁₋₂₀haloalkylene-, —C₁₋₂₀alkoxyalkylene-, C₃₋₂₀cycloalkyl, C₃₋₂₀heterocycloalkyl, aryl, and heteroaryl; and


R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl.

8. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Ik), (II), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



91

-continued




5

5

10

15

(In)




(Io)

wherein:

R^3 is selected from the group consisting of H, $-(CO)-O-$
 C_{1-10} alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl,
 C_{2-10} alkynyl, C_{3-12} cycloalkyl, C_{3-12} heterocycloalkyl, aryl, and heteroaryl.

9. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Im) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



30

35

40

45

wherein:
A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}alkylene)-J-$, $-(CO)-G-(C_{2-10}alkenylene)-J-$, and $-(CO)-G-(C_{2-10}alkynylene)-J-$; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, C_{3-12} heterocycloalkyl, aryl, and heteroaryl;

Q^1 , Q^2 , Q^3 , Q^4 , and Q^5 form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and

R^6 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, C_{3-12} heterocycloalkyl, aryl, and heteroaryl.

10. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (In), (Io), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:




wherein:

R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, C_{3-12} heterocycloalkyl, aryl, and heteroaryl;

Q^1 , Q^2 , Q^3 , Q^4 , and Q^5 form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and

R^6 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, C_{3-12} heterocycloalkyl, aryl, and heteroaryl

11. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Ip) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-$

93



G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:
G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, C₃₋₁₂heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, C₃₋₁₂heterocycloalkyl, aryl, and heteroaryl.

12. The adenosine derivative of embodiment 1, wherein said adenosine derivative is a compound of formula (Iq), (Ir), or a pharmaceutically acceptable salt, tautomer, or solvate









wherein:

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, C₃₋₁₂heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, C₃₋₁₂heterocycloalkyl, aryl, and heteroaryl.







13. The adenosine derivative of embodiment 1, wherein said adenosine derivative is selected from the group consisting of:

94









95

-continued


**96**

-continued



97


-continued



5

10


15



20

25


30



35

40

45



50


55

60

65


98

-continued



5

10



20

25

30

35

40




45

50



55

60

65






99
-continued




and a pharmaceutically acceptable salt, tautomer, or solvate thereof.

13a. The adenosine derivative of embodiment 1 or 13, wherein said adenosine derivative is selected from the group consisting of:




100
-continued



14. The adenosine derivative of any one of embodiments 1-13, wherein said adenosine derivative comprises a reverse transcriptase inhibitor activity in vivo, a reverse transcriptase chain terminator activity in vivo, DNA translocation inhibitor activity in vivo, or a combination thereof.

15. A pharmaceutical composition comprising an adenosine derivative having a structure of formula (I):



wherein:

A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}\text{alkylene})-J-$, $-(CO)-G-(C_{2-10}\text{alkenylene})-J-$, and $-(CO)-G-(C_{2-10}\text{alkynylene})-J-$; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, $-(CO)-G-$;

R^1 is selected from the group consisting of H, $C_{1-20}\text{alkyl}$, $C_{1-20}\text{haloalkyl}$, $C_{1-20}\text{alkoxy}$, $C_{2-20}\text{alkenyl}$, $C_{2-20}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R^2 is selected from the group consisting of H, $C_{1-20}\text{alkyl}$, $C_{1-20}\text{haloalkyl}$, $C_{1-20}\text{alkoxy}$, $C_{2-20}\text{alkenyl}$, $C_{2-20}\text{alkynyl}$, $C_{3-20}\text{cycloalkyl}$, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R^1 and R^2 is not H;

R^1 and R^2 can join together with the atoms to which they are attached to form a 3- to 25-membered heterocyclic ring; and


R^3 is selected from the group consisting of H, $-(CO)-G-C_{1-10}\text{alkyl}$, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

15a. The adenosine derivative of embodiment 15, wherein A is selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, and $-(CO)-G-(C_{1-5}\text{alkylene})-J-$.


15B. The adenosine derivative of embodiment 15 or 15a, wherein A is $-(CO)-G-$ or $-(CO)-G-(C_{1-5}\text{alkylene})-J-$.

101


- 15c. The adenosine derivative of any one of embodiments 15-15b, wherein E is a bond, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-.
 15d. The adenosine derivative of any one of embodiments 15-15c, wherein E is a bond.
 15e. The adenosine derivative of any one of embodiments 15-15d, wherein G is a bond or O.
 15f. The adenosine derivative of any one of embodiments 15-15e, wherein J is a bond or O.
 15g. The adenosine derivative of any one of embodiments 15-15f, wherein G is O and J is a bond.
 15h. The adenosine derivative of any one of embodiments 15-15g, wherein R¹ is H, C₁₋₅alkyl, or adamantly



- 15i. The adenosine derivative of any one of embodiments 15-15h, wherein R¹ is H.
 15j. The adenosine derivative of any one of embodiments 15-15i, wherein R² is H, C₁₋₅alkyl, or adamantly.
 15k. The adenosine derivative of any one of embodiments 15-15j, wherein R² is adamantly



- 15l. The adenosine derivative of any one of embodiments 15-15g, wherein R¹ and R² taken together with the atoms to which they are attached form a 6- to 15-membered heterocyclic ring.
 15m. The adenosine derivative of any one of embodiments 15-15l, wherein R³ is —(CO)—C₁₋₅alkyl, —(CO)—O—C₁₋₅alkyl, or C₁₋₅alkyl.
 15n. The adenosine derivative of any one of embodiments 15-15m, wherein R³ is H.
 16. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Ia), (Ib), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:




(Ia)

102

-continued

(Ib)



wherein:


R¹ is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R² is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R¹ and R² is not H; and

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.


17. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Ic), (Id), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Ic)



103

-continued




wherein:

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, and C₁₋₁₀alkyl;

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

18. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Ie), (If), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

**104**

wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

R² is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;


R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl; and

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

19. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Ig) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Ig)



wherein:

E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;


R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl; and

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

105

20. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Ih) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

5



(Ih)

10

20

25

wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

30

G is selected from the group consisting of a bond, O, NH, and S;

35

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, and —C₂₋₂₀alkynylene-, —C₁₋₂₀haloalkylene-, —C₁₋₂₀alkoxyalkylene-, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and


40

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl.

21. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (II), (Ij), or a pharmaceutically acceptable salt, tautomer, or solvate

45

50



(II)

55


60

65

106

-continued

(Ij)




wherein:

D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, and —C₂₋₂₀alkynylene-, —C₁₋₂₀haloalkylene-, —C₁₋₂₀alkoxyalkylene-, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and


R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl.

22. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Ik), (II), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Ik)



(II)




wherein:

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

107

23. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Im) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and


R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

24. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (In), (Io), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



108

(Io)




wherein:

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

Q¹, Q², Q³, Q⁴, and Q⁵ form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl

25. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Ip) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁶ is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

109

26. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is a compound of formula (Iq), (Ir), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

R^3 is selected from the group consisting of H, $-(CO)-$, $G-C_{1-10}\text{alkyl}$, $C_{1-10}\text{alkyl}$, $C_{1-10}\text{haloalkyl}$, $C_{2-10}\text{alkenyl}$, $C_{2-10}\text{alkynyl}$, $C_{3-12}\text{cycloalkyl}$, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R^6 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

27. The pharmaceutical composition of embodiment 15, wherein said adenosine derivative is selected from the group consisting of compound as disclosed in Table 1 of embodiment 13 and a pharmaceutically acceptable salt, tautomer, or solvate thereof.


28. The pharmaceutical composition of any one of embodiments 15-27, further comprising a pharmaceutically acceptable carrier.

29. The pharmaceutical composition of any one of embodiments 14-27, further comprising an effective dosage of one or more additional antiviral agent selected from lenacapavir, bictegravir, cabotegravir, atazanavir, atazanavir sulfate, darunavir, dolutegravir, doravirine, efavirenz, emtricitabine, tenofovir disoproxil fumarate, tenofovir alafenamide, etravirine, a combination of darunavir and cobicistat, maraviroc, rilpivirine, MK-8507 or a combination thereof.

30. A method for the treatment of a disease, said method comprising administering a subject in need thereof an effective dosage of a pharmaceutical composition com- 65

110

prising an adenosine derivative having a structure of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, $-(CO)-$, $-(CO)-G-$, $-(CO)-G-(C_{1-10}\text{alkylene})-J$, $-(CO)-G-(C_{2-10}\text{alkenylene})-J$, and $-(CO)-G-(C_{2-10}\text{alkynylene})-J$; wherein:

G is selected from the group consisting of a bond, O, NH, and S:

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R^1 is selected from the group consisting of H, C_{1-20} alkyl, C_{1-20} haloalkyl, C_{1-20} alkoxy, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R^2 is selected from the group consisting of H, C_{1-20} alkyl, C_{1-20} haloalkyl, C_{1-20} alkoxy, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R^1 and R^2 is not H;

R^1 and R^2 can join together with the atoms to which they are attached to form a 3- to 25-membered heterocyclic ring; and

R^3 is selected from the group consisting of H, $-(CO)-$, $G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

30a. The adenosine derivative of embodiment 30, wherein A is selected from the group consisting of a bond, $-\text{CO}-$, $-\text{CO}-\text{G}-$, and $-\text{CO}-\text{G}-\text{(C}_{1-5}\text{alkylene)}$.

30b. The adenosine derivative of embodiment 30 or 30a, wherein A is $-(CO)-G-$ or $-(CO)-G-(C_{1-5}\text{alkylene})-$

30c. The adenosine derivative of any one of embodiments 30-30b, wherein E is a bond, $-(CO)-G-$, and $-(CO)-G-(C_{1-5}\text{alkylene})-J-$.

30d. The adenosine derivative of any one of embodiments 30-30c, wherein E is a bond.


30e. The adenosine derivative of any one of embodiments 30-30d, wherein G is a bond or O.

30f. The adenosine derivative of any one of embodiments 30-30e, wherein J is a bond or O.


30g. The adenosine derivative of any one of embodiments 30-30f, wherein G is O and J is a bond.

30h. The adenosine derivative of any one of embodiments 30-30g, wherein R¹ is H, C₁₋₅alkyl, or adamantyl


111




- 30i. The adenosine derivative of any one of embodiments 30-30h, wherein R¹ is H.
- 30j. The adenosine derivative of any one of embodiments 30-30i, wherein R² is H, C₁₋₅alkyl, or adamantly.
- 30k. The adenosine derivative of any one of embodiments 30-30j, wherein R² is adamantly



- 30l. The adenosine derivative of any one of embodiments 30-30g, wherein R¹ and R² taken together with the atoms to which they are attached form a 6- to 15-membered heterocyclic ring.
- 30m. The adenosine derivative of any one of embodiments 30-30l, wherein R³ is —(CO)—C₁₋₅alkyl, —(CO)—O—C₁₋₅alkyl, or C₁₋₅alkyl.
- 30n. The adenosine derivative of any one of embodiments 30-30l, wherein R³ is H.
31. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Ia), (Id), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(Ia)



(Ib)

112

wherein:


R¹ is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R² is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl, wherein at least one of R¹ and R² is not H; and


R³ is selected from the group consisting of H, —(CO)G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

32. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Ic), (Id), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Ic)



(Id)




wherein:

R³ is selected from the group consisting of H, —(CO)G-C₁₋₁₀alkyl, and C₁₋₁₀alkyl;

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

33. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Ie), (If), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;


R² is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl; and

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R⁵ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

34. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Ig) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

E is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;


J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl;

R³ is selected from the group consisting of H, —(CO)—O—C₁₋₁₀alkyl, and C₁₋₁₀alkyl; and

R⁴ is selected from the group consisting of H, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;

35. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Ih) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;


D is selected from the group consisting of —C₁₋₂₀alkylene-, —C₂₋₂₀alkenylene-, and —C₂₋₂₀alky-

115

nylene-, $—C_{1-20}$ haloalkylene-, $—C_{1-20}$ alkoxyalkylene-, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R^3 is selected from the group consisting of H, $—(CO)O—C_{1-10}$ alkyl, and C_{1-10} alkyl. 5

36. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Ii), (Ij), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



(Ii)

10

15

20

25

30

(Ij)


35

40

45

50

60



wherein:


D is selected from the group consisting of $—C_{1-20}$ alkylene-, $—C_{2-20}$ alkenylene-, and $—C_{2-20}$ alkynylene-, $—C_{1-20}$ haloalkylene-, $—C_{1-20}$ alkoxyalkylene-, C_{3-20} cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R^3 is selected from the group consisting of H, $—(CO)O—C_{1-10}$ alkyl, and C_{1-10} alkyl. 65


37. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Ik), (II), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

116

(Ik)



(II)




wherein:

R^3 is selected from the group consisting of H, $—(CO)O—C_{1-10}$ alkyl, C_{1-10} alkyl, $—C_{1-10}$ haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

38. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Im) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:

(Im)



wherein:



A and E are each independently selected from the group consisting of a bond, $—(CO)O—$, $—(CO)G—$, $—(CO)G(C_{1-10}$ alkylene)-J-, $—(CO)G(C_{2-10}$ alkenylene)-J-, and $—(CO)G(C_{2-10}$ alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, $—(CO)G—$;

117

- R^3 is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; 5
 Q^1 , Q^2 , Q^3 , Q^4 , and Q^5 form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and
 R^6 is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloal- 10 kyl, aryl, and heteroaryl.
39. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (In), (Io), or a pharmaceutically acceptable salt, tautomer, or solvate thereof: 15




wherein:

- R^3 is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl;
 Q^1 , Q^2 , Q^3 , Q^4 , and Q^5 form a cyclic ring, wherein said ring is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and
 R^6 is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloal- 65 kyl, aryl, and heteroaryl.

118

40. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Ip) or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



wherein:

- A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:


- G is selected from the group consisting of a bond, O, NH, and S;

- J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

- R^3 is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and


- R^6 is selected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₁₋₁₀alkoxy, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

41. The method of embodiment 30, wherein said adenosine derivative is a compound of formula (Iq), (Ir), or a pharmaceutically acceptable salt, tautomer, or solvate thereof:



119

-continued



wherein:


R^3 is selected from the group consisting of H, $-(CO)-$, $G-C_{1-10}$ alkyl, C_{1-10} alkyl, C_{1-10} haloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl; and

R^6 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} haloalkyl, C_{1-10} alkoxy, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

42. The method of embodiment 30, wherein said adenosine derivative is selected from the group consisting of compound as disclosed in Table 1 of embodiment 13 and a pharmaceutically acceptable salt, tautomer, or solvate thereof.

43. The method of any one of embodiments 30-42, said pharmaceutical composition is administered to said subject via intramuscular (IM) injection, subcutaneous (SC) injection, intravenous (IV) injection, oral administration, topical application, implant application or a combination thereof.


44. The method of any one of embodiments 30-43, further comprising measuring a specimen of said subject to determine a measured level of a target drug in said specimen, wherein said target drug has a formula (T-1), wherein X is a halogen selected from the group consisting of F, Cl, Br and I:



or a pharmaceutically acceptable salt, stereoisomer, tautomer thereof

45. The method of embodiment 44, wherein said target drug has a formula (T-1A):

120



or a pharmaceutically acceptable salt, stereoisomer, tautomer thereof.

46. The method of embodiment 44, wherein said target drug is (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol, or a pharmaceutically acceptable salt thereof.

47. The method of any one of embodiments 44-46, further comprising adjusting said effective dosage to produce a modified effective dosage if said measured level of said target drug is different from a predetermined target level of said target drug and administering said modified effective dosage to said subject.

48. The method of any one of embodiments 30-47, wherein said disease is Acquired Immune Deficiency Syndrome (AIDS), wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, or multidrug resistant HIV.

49. The method of any one of embodiments 30-48, further comprising administering said subject an effective dosage of one or more additional anti-HIV agents selected from lenacapavir, bictegravir, cabotegravir, atazanavir, atazanavir sulfate, darunavir, dolutegravir, doravirine, efavirenz, emtricitabine, tenofovir disoproxil fumarate, tenofovir alafenamide, etravirine, a combination of darunavir and cobicistat, maraviroc, rilpivirine, MK-8507 or a combination thereof.

50. The method of embodiment 49, wherein said adenosine derivative and said one or more additional anti-HIV agents are administered to said subject together or separately via oral administration, parenteral administration or a combination thereof.

51. The method of embodiment 50, wherein said adenosine derivative and said one or more additional anti-HIV agents are administered to said subject with a daily, weekly, biweekly, monthly, bimonthly, or semiannually administration schedule.

52. Use of the adenosine derivative of any one of embodiments 1-14 for manufacturing a medicament for treating a disease, wherein said disease is Acquired Immune Deficiency Syndrome (AIDS), wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, or multidrug resistant HIV.

53. A use of the pharmaceutical composition of any one of embodiments 15-29 for the treatment of a disease in a subject in need thereof, wherein said disease is Acquired Immune Deficiency Syndrome (AIDS), wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, or multidrug resistant HIV.

54. A use of the method of any one of embodiments 30-51 for the treatment of a disease in a subject in need thereof, wherein said disease is Acquired Immune Deficiency Syndrome (AIDS), wild-type HIV-1, NRTI-

121

- resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, or multidrug resistant HIV.
55. A method for the prevention of infection in a subject in need thereof, said method comprising administering said subject an effective dosage of a pharmaceutical composition of any one of embodiments 15-29, wherein said subject is free from detectable symptoms of said infection.
56. The method of embodiment 55, wherein said infection comprises a disease selected from Acquired Immune Deficiency Syndrome (AIDS), an infection of wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, or multidrug resistant HIV, or a combination thereof.
57. The method of embodiment 55, wherein said detectable symptoms comprise symptoms of Acquired Immune Deficiency Syndrome (AIDS), symptoms of infection of HIV viruses comprising wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, multidrug resistant HIV, or a combination thereof.
58. The method of embodiment 55, wherein said pharmaceutical composition administered to said subject with a daily, weekly, biweekly, monthly, bimonthly, or semiannually administration schedule.
59. The method of embodiment 58, further comprising administering said subject an effective dosage of one or more additional anti-HIV agents selected from lenacapavir, atazanavir, atazanavir sulfate, bictegravir, cabotegravir, darunavir, dultegravir, doravirine, efavirenz, tenofovir disoproxil fumarate, tenofovir alafenamide, etravirine, a combination of darunavir and cobicistat, maraviroc, rilpivirine, or a combination thereof.
60. The method of embodiment 59, wherein said one or more additional anti-HIV agents are administered to said subject together with said pharmaceutical composition or separately.
61. A method for treating HIV infection, comprising: administering a subject in need thereof an effective dosage of the pharmaceutical composition of any one of embodiment 1-29.
62. A method for preventing HIV infection, comprising: administering a subject in need thereof an effective dosage of the pharmaceutical composition of any one of embodiment 1-29.
63. The method of embodiment 61 or 62, wherein the HIV infection is caused by wild-type HIV-1, NRTI-resistant HIV-1, HIV-2, HIV having M184V mutations, HIV having K65R, or multidrug resistant HIV.
64. The method of any one of embodiment 61-63, wherein the administration is by oral administration.
65. The method of any one of embodiment 61-63, wherein the administration is by parenteral administration.
66. The method of embodiment 65, wherein the parenteral administration is by intramuscular or subcutaneous injection.
67. The method of any one of embodiments 61-66, wherein the administration of the pharmaceutical composition results in a higher plasma concentration of EFdA when compared to administration of a dose-equivalent EFdA under the same condition.
68. The method of embodiment 67, wherein the administration of the pharmaceutical composition results in at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or 200% higher plasma concentration of EFdA when compared to administration of a dose-equivalent EFdA under the same condition.

122


69. The method of embodiment 67, wherein the administration of the pharmaceutical composition results in 50%-80%, 50%-100%, or 50%-200% higher plasma concentration of EFdA when compared to administration of a dose-equivalent EFdA under the same condition.
70. The method of any one of embodiments 61-69, wherein the administration of the pharmaceutical composition results in a prolonged release of EFdA when compared to administration of a dose-equivalent EFdA under the same condition.
71. The method of any one of embodiments 61-70, wherein the administration of the pharmaceutical composition results in a higher AUC of EFdA when compared to administration of a dose-equivalent EFdA under the same condition.
72. The method of embodiment 71, wherein the administration of the pharmaceutical composition results in at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% higher AUC of EFdA when compared to administration of a dose-equivalent EFdA under the same condition.
73. The method of embodiment 71, wherein the administration of the pharmaceutical composition results in 50%-200%, 50%-150%, or 80%-120% higher AUC of EFdA when compared to administration of a dose-equivalent EFdA under the same condition.

The instant disclosure now will be exemplified in the following non-limiting examples.

EXAMPLES

The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various uses and conditions.

Example 1: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl) acetate (compound 1)





123

Preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl) acetate

To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-3-ol (50 mg, 0.17 mmol, 1 eq) in pyridine (2 mL) was added 2-(1-adamantyl)acetyl chloride (39.9 mg, 0.19 mmol, 1.1 eq) slowly at 0° C. The resulting mixture was stirred at 20° C. for 5 h. The reaction mixture was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, eluted with 0-5% MeOH/DCM @ 30 mL/min) to give ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl) acetate (17.9 mg, 22.4% yield) as a white solid. LCMS (ESI) m/z, C₂₄H₂₈FN₅O₄; calculated 469.21, found (M+H)⁺: 470.1. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.97 (s, 1H), 6.36 (br s, 2H), 6.26-6.23 (m, 1H), 4.76 (q, J=7.2 Hz, 1H), 4.27 (q, J=12 Hz, 2H), 3.72 (d, J=6.4 Hz, 1H), 2.98 (s, 1H), 2.91-2.89 (m, 1H), 2.59-2.55 (m, 1H), 2.22 (s, 1H), 1.84 (br s, 3H), 1.69-1.52 (m, 7H), 1.52-1.42 (m, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.74 (s, 1F).

Example 2: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate (Compound 2)




Preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate

To a solution of [(2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methyl (4-nitrophenyl) carbonate (330 mg, 0.72 mmol, 1 eq) in THE (15 mL) was added DMAP (8.80 mg, 0.072 mol, 0.1 eq) and 1-adamantylmethanol (299 mg, 1.80 mmol, 2.5 eq). The resulting mixture was stirred at 20° C. for 2 h. The reaction mixture was concentrated. The resulting residue was purified by prep-HPLC (column: Phenomenex Gemini-NX 80×30 mm×3 um; mobile phase: [water (10 mM


124

NH₄HCO₃]-ACN]; B %: 40%-70%, 9 min) to give ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate (11.1 mg, 3.2% yield) as a white solid. LCMS (ESI) m/z, C₂₄H₂₈FN₅O₅; calculated 485.21, found (M+H)⁺: 486.2. ¹H NMR (400 MHz, CD₃OD) δ (ppm) 8.15 (s, 1H), 6.35-6.32 (m, 1H), 4.86-4.83 (m, 1H), 4.61 (br s, 1H), 4.42 (q, J=12 Hz, 2H), 3.73-3.66 (m, 1H), 3.64-3.56 (m, 1H), 3.20 (s, 1H), 2.87-2.85 (m, 1H), 2.70-2.65 (m, 1H), 1.95 (s, 3H), 1.79-1.72 (m, 3H), 1.71-1.64 (m, 3H), 1.52 (s, 6H). ¹⁹F NMR (376 MHz, CD₃OD) δ (ppm) -52.90 (s, 1F).

Example 3: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl adamantan-1-carboxylate (Compound 3)



-continued



125

Preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl adamantane-1-carboxylate


To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (500 mg, 1.71 mmol, 1 eq) in pyridine (5 mL) was added adamantane-1-carbonyl chloride (4.51 g, 22.7 mmol, 13. eq) in THE (10 mL) at 0° C. The resulting mixture was stirred at 0° C. for 2 h. The reaction mixture was quenched with H₂O (60 mL) and extracted with DCM (70 mL). The organic layer was washed with H₂O (60 mL), brine (60 mL), dried over Na₂SO₄, and concentrated. The resulting residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluted with 0-8% methanol/dichloromethane gradient @ 40 mL/min) to give ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl adamantane-1-

carboxylate (172 mg, 21.7% yield) as a white solid. LCMS (ESI) m/z, C₂₃H₂₆FN₅O₄; calculated 455.20, found (M+H)⁺: 456.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.98 (s, 1H), 6.32 (br s, 2H), 6.25-6.22 (m, 1H), 4.75-4.69 (m, 1H), 4.27 (q, J=12 Hz, 2H), 3.71-3.70 (m, 1H), 2.97 (s, 1H), 2.97-2.90 (m, 1H), 2.62-2.56 (m, 1H), 1.75-1.54 (m, 15H).

¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.72 (s, 1F).


126

Example 4, Example 5 and Example 6: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantyl carbonate (Compound 4), ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 1-adamantyl carbonate (Compound 5) and (((2R,3S,5R)-3-(((1-adamantyl oxy)carbonyloxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl) 1-adamantyl carbonate (Compound 6)






127

Preparation of 1-adamantyl (4-nitrophenyl) carbonate

**128**

To a solution of (4-nitrophenyl) carbonochloridate (992 mg, 4.92 mmol, 1.5 eq) in MeCN (15 mL) was added pyridine (10.6 mL, 131 mmol, 40 eq) and adamantan-1-ol (500 mg, 3.28 mmol, 1 eq). The resulting mixture was stirred at 20° C. for 4 h and then concentrated. The resulting residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, eluted with 0-10% ethyl acetate/petroleum ether gradient @ 30 mL/min) to give 1-adamantyl (4-nitrophenyl) carbonate (868 mg, 83.4% yield) as a white solid.

Preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantyl carbonate, ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 1-adamantyl carbonate and (((2R,3S,5R)-3(((1-adamantyl)oxy)carbonyloxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl) 1-adamantyl carbonate



129

To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (100 mg, 0.34 mol, 1 eq) in THE (20 mL) was added DMAP (8.32 mg, 0.068 mol, 0.2 eq) and 1-adamantyl (4-nitrophenyl) carbonate (162 mg, 0.51 mol, 1.5 eq). The resulting mixture was stirred at 20° C. for 32 h and then concentrated. The resulting residue was purified by prep-HPLC (column: Phenomenex Gemini-NX 80×30 mm×3 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 49%-79%, 9 min) to give three products.

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 1-adamantyl carbonate (16.5 mg, 10.3% yield, white solid): LCMS (ESI) m/z, C₂₃H₂₆FN₅O₅; calculated 471.19, found (M+H)⁺: 472.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.95 (s, 1H), 6.32 (br s, 2H), 6.24-6.23 (m, 1H), 4.75 (q, J=7.2 Hz, 1H), 4.44 (d, J=12 Hz, 1H), 4.14 (d, J=12 Hz, 1H), 3.70 (d, J=6.4 Hz, 1H), 2.98 (s, 1H), 2.85-2.84 (m, 1H), 2.60-2.50 (m, 1H), 2.14-2.07 (m, 5H), 1.92-1.85 (m, 4H), 1.63 (s, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.78 (s, 1F).




((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 1-adamantyl carbonate (7.8 mg, 4.87% yield, white solid). LCMS (ESI) m/z, C₂₃H₂₆FN₅O₅; calculated 471.19, found (M+H)⁺: 472.1. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.98 (s, 1H), 6.44 (br s, 2H), 6.37-6.33 (m, 1H), 5.49-5.47 (m, 1H), 20 25

130

5.09-5.05 (m, 1H), 3.90-3.75 (m, 2H), 3.05-3.01 (m, 1H), 2.99 (s, 1H), 2.59-2.57 (m, 1H), 2.15 (s, 8H), 1.71 (s, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -53.38 (s, 1F).


((2R,3S,5R)-3-(((1-adamantyl)oxy)carbonyl)oxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-2-yl)methyl 1-adamantyl carbonate (4.2 mg, 1.90% yield, white solid). LCMS (ESI) m/z, C₃₄H₄₀FN₅O₇; calculated 649.29, found (M+H)⁺: 650.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.96 (s, 1H), 6.35 (br s, 2H), 6.31-6.28 (m, 1H), 5.58 (t, J=6.4 Hz, 1H), 4.35 (q, J=11.6 Hz, 2H), 3.14-3.12 (m, 1H), 3.04 (s, 1H), 2.77-2.68 (m, 1H), 2.19 (s, 3H), 2.13 (s, 9H), 2.02-2.05 (m, 5H), 1.91 (s, 1H), 1.72-1.59 (m, 12H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.46 (s, 1F).

Example 7, Example 8 and Example 9: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl)ethyl carbonate (Compound 7), ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate (Compound 8) and ((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate (Compound 9)



131

-continued



132

15

The title compounds were prepared following the procedures of preparation of Example 4, Example 5 and Example 6, substituting 1-adamantyl (4-nitrophenyl) carbonate with 2-(1-adamantyl)ethyl (4-nitrophenyl) carbonate. 2-(1-Adamantyl)ethyl (4-nitrophenyl) carbonate was prepared similarly as 1-adamantyl (4-nitrophenyl) carbonate, except replacing adamantan-1-ol with 2-(1-adamantyl)ethanol.



((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl)ethyl carbonate (12.7 mg, 14.9% yield, white solid). LCMS (ESI) m/z, C₂₅H₃₀FN₅O₅: calculated 499.22, found (M+H)⁺: 500.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.95 (s, 1H), 6.29 (br s, 2H), 6.27-6.24 (m, 1H), 4.76-4.71 (m, 1H), 4.36 (q, J=12 Hz, 2H), 4.13-4.02 (m, 2H), 3.69 (d, J=6.4 Hz, 1H), 2.99 (s, 1H), 2.87-2.81 (m, 1H), 2.63-2.50 (m, 1H), 1.91 (s, 3H), 1.75-1.58 (m, 6H), 1.49 (s, 6H), 1.35-1.31 (m, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.84 (s, 1F).

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate (5.9 mg, 6.93% yield, white solid). LCMS (ESI) m/z, C₂₅H₃₀FN₅O₅: calculated 499.22, found (M+H)⁺: 500.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.95 (s, 1H), 6.42 (br s, 2H), 6.38-6.31 (m, 1H), 5.51-5.49 (m,

1H), 5.01-4.97 (m, 1H), 4.27-4.21 (m, 2H), 3.86-3.74 (m, 2H), 3.04-3.02 (m, 1H), 2.95 (s, 1H), 2.59-2.54 (m, 1H), 1.77-1.61 (m, 8H), 1.56 (m, 6H), 1.49-1.46 (m, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -53.33 (s, 1F).

20 ((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyloxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) 2-(1-adamantyl)ethyl carbonate (4.2 mg, 3.49% yield, white solid). LCMS (ESI) m/z, C₃₈H₄₈FN₅O₇: calculated 705.35, found (M+H)⁺: 706.3. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.95 (s, 1H), 6.32-6.29 (m, 3H), 5.66-5.63 (m, 1H), 4.42 (q, J=11.6 Hz, 2H), 4.28-4.22 (m, 2H), 4.16-4.03 (m, 2H), 3.19-3.08 (m, 1H), 3.03 (s, 1H), 2.76-2.65 (m, 1H), 1.91 (s, 4H), 1.76-1.60 (m, 13H), 1.59-1.44 (m, 15H), 1.35 (t, J=7.2 Hz, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.54 (s, 1F).



Example 10 and Example 11: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate (Compound 10) and ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 3-(1-adamantyl)propyl carbonate (Compound 11)




133

134

-continued




Preparation of 3-(1-adamantyl)propyl
(4-nitrophenyl) carbonate



3-(1-adamantyl)propan-1-ol was prepared from 1-adamantylmethanol according to literature procedures (WO 2011/058582 A1).

To a solution of 3-(1-adamantyl)propan-1-ol (100 mg, 0.51 mmol, 1 eq) in MeCN (2 mL) was added pyridine (1.63 g, 20.6 mmol, 40 eq) and (4-nitrophenyl) carbonochloride (207 mg, 1.03 mmol, 2 eq). The resulting mixture was stirred at room temperature for 4 h and then was concentrated. The resulting residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, eluted with 0-30% ethyl acetate/petroleum ether gradient @ 15 mL/min) to give 3-(1-adamantyl)propyl (4-nitrophenyl) carbonate (130 mg, 70.9% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.31-8.27 (m, 2H), 7.41-7.37 (m, 2H), 4.28-4.25 (m, 2H), 2.00-1.94 (m, 3H), 1.77-1.69 (m, 5H), 1.65-1.61 (m, 3H), 1.52-1.47 (m, 6H), 1.18-1.14 (m, 2H).



Preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate and ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl)-3-(1-adamantyl)propyl carbonate



135

136

-continued




To a solution of 3-(1-adamantyl)propyl (4-nitrophenyl) carbonate (91.6 mg, 0.255 mmol, 1.5 eq) and (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (50 mg, 0.17 mmol, 1 eq) in THE (2 mL) was added DMAP (4.15 mg, 0.034 mmol, 0.2 eq). The resulting mixture was stirred at room temperature for 32 h, and then was concentrated. The resulting residue was purified by prep-HPLC (column: Phenomenex Gemini-NX 80×30 mm×3 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 60%-90%, 9 min) to give two products.

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate (4.5 mg, 5.2% yield) was obtained as a white solid. LCMS (ESI) m/z, C₂₆H₃₂FN₅O₅; calculated 513.24, found (M+H)⁺: 514.3. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.95 (s, 1H), 6.43-6.40 (m, 1H), 6.08-6.01 (m, 2H), 4.77-4.74 (m, 1H), 4.54-4.46 (m, 2H), 4.15-4.11 (m, 2H), 2.95-2.89 (m, 1H), 2.83-2.75 (m, 1H), 2.72-2.66 (m, 1H), 2.50-2.45 (m, 1H), 1.99-1.90 (m, 3H), 1.72-1.69 (m, 3H), 1.65-1.60 (m, 3H), 1.46-1.43 (m, 6H), 1.30-1.26 (m, 1H), 1.12-1.06 (m, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm) -49.39 (s, 1F).

²⁵ ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 3-(1-adamantyl)propyl carbonate (3.6 mg, 4.1% yield) was obtained as a white solid. LCMS (ESI) m/z, C₂₆H₃₂FN₅O₅; calculated 513.24, found (M+H)⁺: 514.2. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.95 (s, 1H), 6.40-6.37 (m, 1H), 6.13-6.08 (m, 2H), 5.65-5.64 (m, 1H), 4.23-4.15 (m, 2H), 4.10-4.07 (m, 1H), 3.99-3.96 (m, 1H), 3.28-3.20 (m, 1H), 2.70-2.65 (m, 1H), 2.62-2.57 (m, 1H), 2.01-1.95 (m, 3H), 1.75-1.72 (m, 3H), 1.70-1.68 (m, 1H), 1.65-1.62 (m, 3H), 1.50-1.45 (m, 7H), 1.17-1.13 (m, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm) -49.66 (s, 1F).



Example 12 and Example 13: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butyl carbonate (Compound 12) and ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl) 4-(1-adamantyl)butyl carbonate (Compound 13)



137

138

-continued




((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butyl carbonate and ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-3-yl) 4-(1-adamantyl)butyl carbonate were prepared using the same procedure as in the preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate and ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-3-yl) 3-(1-adamantyl)propyl carbonate, substituting 3-(1-adamantyl)propan-1-ol with 4-(1-adamantyl) butan-1-ol. 4-(1-Adamantyl)butan-1-ol was prepared from 2-(1-adamantyl)ethanol according to literature procedures (WO 2011/058582 A1).

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butyl carbonate (4.6 mg, 5.1% yield, white solid). LCMS (ESI) m/z, C₂₇H₃₄FN₅O₅: calculated 527.25, found 45 (M+H)⁺: 528.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.95 (s, 1H), 6.28-6.25 (m, 3H), 4.75-4.70 (m, 1H), 4.47-4.44 (m, 1H), 4.29-4.26 (m, 1H), 4.07-4.00 (m, 2H), 3.70-3.68 (m, 1H), 3.01-2.96 (m, 1H), 2.86-2.80 (m, 1H), 2.60-2.53 (m, 1H), 1.95-1.90 (m, 3H), 1.72-1.69 (m, 3H), 1.64-1.61 (m, 3H), 1.53-1.48 (m, 2H), 1.45-1.44 (m, 6H), 1.28-1.20 (m, 2H), 1.05-1.00 (m, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.85 (s, 1F).

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-3-yl) 4-(1-adamantyl)butyl carbonate (6.4 mg, 7.1% yield, white solid). LCMS (ESI) m/z, C₂₇H₃₄FN₅O₅: calculated 527.25, found (M+H)⁺: 528.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.95 (m, 1H), 6.40-6.32 (m, 3H), 5.52-5.49 (m, 1H), 4.99-4.96 (m, 1H), 4.20-4.13 (m, 2H), 3.88-3.84 (m, 1H), 3.80-3.74 (m, 1H), 3.08-3.00 (m, 1H), 2.97-2.92 (m, 1H), 2.60-2.55 (m, 1H), 1.95-1.90 (m, 3H), 1.77-1.71 (m, 3H), 1.66-1.59 (m, 5H), 1.50-1.43 (m, 6H), 1.37-1.29 (m, 2H), 1.11-1.06 (m, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -53.34 (s, 1F).

Example 14: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propanoate (Compound 14)




((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propanoate was prepared (65.1 mg, 53.9% yield, white solid) using the same procedure as in the preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl) acetate, substituting 2-(1-adamantyl)acetyl chloride with 3-(1-adamantyl) propanoyl chloride. 3-(1-Adamantyl) propanoyl chloride was synthesized from methyl 3-(1-adamantyl) propanoate according to literature procedures (WO 2011/058582 A1).

LCMS (ESI) m/z, C₂₅H₃₀FN₅O₄: calculated 483.23, found (M+H)⁺: 484.2. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.10 (s, 1H), 6.36-6.25 (m, 3H), 4.79-4.75 (m, 1H), 4.50-4.42 (m, 2H), 3.00-2.94 (m, 1H), 2.84-2.79 (m, 1H), 2.76-

139

2.68 (m, 1H), 2.33-2.28 (m, 2H), 1.97-1.93 (m, 3H), 1.71-1.68 (m, 3H), 1.62-1.59 (m, 3H), 1.44-1.43 (m, 6H), 1.40-1.38 (m, 3H). ^{19}F NMR (376 MHz, CDCl_3) δ (ppm)-48.80 (s, 1F).



Example 15: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butanoate (Compound 15)

**140**

((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 4-(1-adamantyl)butanoate was prepared (61.4 mg, 51.7% yield, a white solid) using the same procedure as in the preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propanoate, substituting 3-(1-adamantyl) propanoyl chloride with 4-(1-adamantyl) butanoyl chloride. 4-(1-Adamantyl) butanoyl chloride was synthesized from methyl 4-(1-adamantyl)butanoate according to literature procedures (WO 2011/058582 A1).


LCMS (ESI) m/z, $\text{C}_{26}\text{H}_{32}\text{FN}_5\text{O}_4$: calculated 497.24, found ($\text{M}+\text{H}$): 498.3. ^1H NMR (400 MHz, CD_3CN) δ (ppm) 7.96 (s, 1H), 6.30 (br s, 2H), 6.26-6.23 (m, 1H), 4.78-4.73 (m, 1H), 4.41 (d, $J=12.0$ Hz, 1H), 4.20 (d, $J=11.6$ Hz, 1H), 3.64 (d, $J=6.4$ Hz, 1H), 2.98 (s, 1H), 2.83-2.81 (m, 1H), 2.61-2.57 (m, 1H), 2.23-2.19 (m, 1H), 1.93-1.85 (m, 3H), 1.71-1.68 (m, 3H), 1.63-1.60 (m, 3H), 1.46-1.38 (m, 8H), 0.95-0.90 (m, 2H). ^{19}F NMR (376 MHz, CD_3CN) δ (ppm) -52.81 (s, 1F).

Example 16: (10aR,12R,13aS)-12-(6-amino-2-fluoro-9H-purin-9-yl)-10a-ethynylhexahydro-4H,10H-furo[3,2-d][1,3,7,9]tetraoxacyclododecene-2,8-dione (Compound 16)




141

-continued



Preparation of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(((4-nitrophenoxy)carbonyl)oxy)methyltetrahydrofuran-3-yl (4-nitrophenyl) carbonate




15

To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (150 mg, 0.512 mmol, 1 eq) in MeCN (15 mL) was added 20 pyridine (1.62 g, 20.4 mmol, 1.65 mL, 40 eq) and (4-nitrophenyl) carbonochloridate (619 mg, 3.07 mmol, 6 eq). The resulting mixture was stirred at 15° C. for 41 h. The reaction 25 mixture was concentrated and purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluted with 0-5% Methanol/DCM gradient @ 50 mL/min) to give (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin- 30 9-yl)-2-ethynyl-2-(((4-nitrophenoxy)carbonyl)oxy)methyl tetrahydrofuran-3-yl (4-nitrophenyl) carbonate (250 mg, 78.3% yield) as a white solid.


40

Preparation of (10aR,12R,13aS)-12-(6-amino-2-fluoro-9H-purin-9-yl)-10a-ethynylhexahydro-4H, 10H-furo[3,2-d][1,3,7,9]tetraoxacyclododecine-2,8-dione



142


-continued



15

To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(((4-nitrophenoxy)carbonyl)oxy)methyltetrahydrofuran-3-yl (4-nitrophenyl) carbonate (300 mg, 0.481 mmol, 1 eq) in MEK (30 mL) was added DMAP (58.8 mg, 0.481 mmol, 1 eq) and propane-1,3-diol (32.9 mg, 0.433 mmol, 0.9 eq). The resulting mixture was stirred at 20° C. for 18 h. The reaction mixture was concentrated and purified by prep-HPLC (column: Welch Xtimate C18 150×25 mm×5 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 17%-47%, 9 min) to give (10aR,12R,13aS)-12-(6-amino-2-fluoro-9H-purin-9-yl)-10a-ethynylhexahydro-4H,10H-furo[3,2-d][1,3,7,9]tetraoxacyclododecene-2,8-dione (5.2 mg, 2.56% yield, white solid). LCMS (ESI) m/z, C₁₁H₁₆FN₅O₅; calculated 421.10, found (M+H)⁺: 422.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.96 (s, 1H), 6.34 (br s, 2H), 6.32-6.29 (m, 1H), 6.05-6.01 (m, 1H), 4.57-4.53 (m, 2H), 4.41-4.37 (m, 4H), 3.11 (s, 1H), 2.97-2.94 (m, 1H), 2.85-2.80 (m, 1H), 2.21-2.19 (m, 1H), 2.13-1.94 (m, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.39 (s, 1F).

Example 17: (11aR,13R,14aS)-13-(6-amino-2-fluoro-9H-purin-9-yl)-11a-ethynyloctahydro-11H-furo[3,2-d][1,3,7]trioxacyclotridecene-2,9(4H)-dione (Compound 17)



40

45

50




55

60

65


Preparation of tert-butyl 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-[[tert-butyl(dimethyl)silyloxy)methyl]-2-ethynyl-tetrahydrofuran-3-yl]oxycarbonyloxyhexanoate

-continued




145

-continued

5
10**146**

-continued



15

tert-Butyl 6-(4-nitrophenoxy)carbonyloxyhexanoate was prepared using the same procedure as in the preparation of 3-(1-adamantyl)propyl (4-nitrophenyl) carbonate, substituting 3-(1-adamantyl)propan-1-ol with tert-butyl 6-hydroxyhexanoate. tert-Butyl 6-hydroxyhexanoate was synthesized from oxepan-2-one according to literature procedure (WO2015187596 A2).

To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-ethynyltetrahydrofuran-3-ol (200 mg, 0.49 mmol, 1 eq) in MeCN (20 mL) was added DMAP (60.0 mg, 0.49 mmol, 1 eq), Et₃N (149 mg, 1.47 mmol, 3 eq) and tert-butyl 6-(4-nitrophenoxy)carbonyloxyhexanoate (346 mg, 0.98 mmol, 2 eq). The resulting mixture was stirred at 15° C. for 16 h. The reaction mixture was concentrated and purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluted with 0-3% MeOH/DCM @ 30 mL/min) to give tert-butyl 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-ethynyltetrahydrofuran-3-yl]oxycarbonyloxyhexanoate (250 mg, 81.9% yield) as a yellow solid. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 8.22 (s, 1H), 6.52-6.48 (m, 1H), 6.08 (br s, 2H), 5.50-5.48 (m, 1H), 4.25-4.17 (m, 2H), 4.00 (q, J=12 Hz, 2H), 2.82-2.79 (m, 2H), 2.70 (s, 1H), 2.26-2.22 (m, 2H), 1.75-1.71 (m, 2H), 1.65-1.61 (m, 2H), 1.47-1.43 (m, 11H), 0.93 (s, 9H), 0.14 (s, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) 49.79 (s, 1F).



To a solution of tert-butyl 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-ethynyltetrahydrofuran-3-yl]oxycarbonyloxyhexanoate (80 mg, 0.16 mmol, 1 eq) in THE (5 mL) was added TBAF (1 M in THF, 0.25 mL, 1.5 eq). The resulting mixture was stirred at 15° C. for 1 h. The reaction mixture was concentrated and purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, eluted with 0-4% ethyl acetate/petroleum ether gradient @ 25 mL/min) to give tert-butyl 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxycarbonyloxyhexanoate (80 mg, 98.0% yield) as a light yellow gum. To a solution of tert-butyl 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxycarbonyloxyhexanoate (80 mg, 0.16 mmol, 1 eq) in DCM (20 mL) was added TFA (1 mL). The resulting mixture was stirred at 15° C. for 16 h. The reaction mixture was concentrated and purified by prep-TLC (silica gel, DCM/MeOH=10/1) to give 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxycarbonyloxyhexanoic acid (60 mg, 84.3% yield) as a yellow gum.

45

Preparation of 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxycarbonyloxyhexanoic acid


Preparation of (11aR,13R,14aS)-13-(6-amino-2-fluoro-9H-purin-9-yl)-11a-ethynyloctahydro-11H-furo[3,2-d][1,3,7]trioxacyclotridecene-2,9(4H)-dione

50

55
60
65


147

-continued




To a solution of 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxycarbonyloxyhexanoic acid (60 mg, 0.13 mmol, 1 eq) in DCM (6 mL) and ACN (6 mL) was added TCFH (104 mg, 0.37 mmol, 2.8 eq) and NMI (36.0 mg, 0.44 mmol, 3.3 eq). The resulting mixture was stirred at 25° C. for 16 h. The reaction mixture was concentrated and purified by prep-HPLC (NH_4HCO_3 condition; column: Welch Xtimate C18 150×25 mm×5 um; mobile phase: [water (10 mM NH_4HCO_3)-ACN]; B %: 32%-62%, 9 min) to give (11aR, 25 13R,14aS)-13-(6-amino-2-fluoro-9H-purin-9-yl)-11a-ethynylcyclotriphosphazene-2,9(4H)-dione (3.4 mg, 6.03% yield, a white solid). LCMS (ESI) m/z, $\text{C}_{19}\text{H}_{20}\text{FN}_5\text{O}_6$: calculated 433.14, found (M+H)⁺: 434.1. ¹H NMR (400 MHz, CD_3CN) δ (ppm) 7.95 (s, 1H), 6.34-6.30 (m, 3H), 5.65-5.62 (m, 1H), 4.43 (q, $J=11.6$ Hz, 2H), 4.24-4.20 (m, 2H), 4.12-4.06 (m, 2H), 3.18-3.11 (m, 1H), 3.04 (s, 1H), 2.74-2.70 (m, 1H), 1.93-1.84 (m, 3H), 1.74-1.61 (m, 6H), 1.54-1.65 (m, 6H), 1.36-1.28 (m, 5H). ¹⁹F NMR (376 MHz, CD_3CN) δ (ppm) -52.54 (s, 1F).

Example 18: ((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) ethyl carbonate (Compound 18)

**148**


((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) ethyl carbonate was prepared (11.2 mg, 19.6% yield, a white solid) using the same procedure as in the preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl) acetate, substituting 2-(1-adamantyl)acetyl chloride with ethyl carbonochloridate. LCMS (ESI) m/z, $\text{C}_{28}\text{H}_{34}\text{FN}_5\text{O}_7$: calculated 571.24, found (M+H)⁺: 572.3. ¹H NMR (400 MHz, CD_3CN) δ (ppm) 7.95 (s, 1H), 6.34-6.30 (m, 3H), 5.65-5.62 (m, 1H), 4.43 (q, $J=11.6$ Hz, 2H), 4.24-4.20 (m, 2H), 4.12-4.06 (m, 2H), 3.18-3.11 (m, 1H), 3.04 (s, 1H), 2.74-2.70 (m, 1H), 1.93-1.84 (m, 3H), 1.74-1.61 (m, 6H), 1.54-1.65 (m, 6H), 1.36-1.28 (m, 5H). ¹⁹F NMR (376 MHz, CD_3CN) δ (ppm) -52.54 (s, 1F).

Example 19: ((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl) isobutyrate (Compound 19)



149


-continued



10

150


-continued



15

((2R,3S,5R)-2-(((2-(1-adamantyl)ethoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl isobutyrate was prepared (12.8 mg, 22.5% yield, a white solid) using the same procedure as in the preparation of ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl)methyl 2-(1-adamantyl) acetate, substituting 2-(1-adamantyl)acetyl chloride with isobutyryl chloride. LCMS (ESI) m/z, C₂₉H₃₆FN₅O₆; calculated 569.26, found (M+H)+: 570.3. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.98 (s, 1H), 6.38 (br s, 2H), 6.35-6.32 (m, 1H), 5.73-5.70 (m, 1H), 4.41 (q, J=12 Hz, 2H), 4.13-4.06 (m, 2H), 3.12-3.08 (m, 1H), 3.06 (s, 1H), 2.69-2.64 (m, 2H), 1.95-1.90 (m, 3H), 1.74-1.58 (m, 6H), 1.50 (s, 6H), 1.40-1.32 (m, 2H), 1.24-1.16 (m, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.63 (s, 1F).


20




25

Preparation of 1-adamantylmethyl (2,3,4,5,6-pentafluorophenyl) carbonate


Example 20: ((2R,3S,5R)-2-(((1-adamantyl)methoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl isobutyrate (Compound 20)




35




40




45



50




55





To a solution of 1-adamantylmethanol (1.00 g, 6.01 mmol, 1 eq) in pyridine (5 mL) and MeCN (5 mL) was added bis(2,3,4,5,6-pentafluorophenyl) carbonate (3.08 g, 7.82 mmol, 1.3 eq). The reaction mixture was stirred at 15° C. for 16 h and then was concentrated. The resulting residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0-1% ethyl acetate/petroleum ether gradient @25 mL/min) to give 1-adamantylmethyl (2,3,4,5,6-pentafluorophenyl) carbonate (2.20 g, 98% yield) as a white solid.

151

Preparation of 1-adamantylmethyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methyl carbonate


**152**

-continued




To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (200 mg, 0.68 mmol, 1 eq) in pyridine (2 mL) and DCM (0.5 mL) was added DMAP (8.33 mg, 0.068 mmol, 0.1 eq) and 1-adamantylmethyl (2,3,4,5,6-pentafluorophenyl) carbonate (898 mg, 2.39 mmol, 3.5 eq) at 0° C. The reaction mixture was stirred at 15° C. for 20 h. The resulting mixture was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, eluent of 0-1.5% MeOH/DCM @ 35 mL/min) to give 1-adamantylmethyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methyl carbonate (150 mg, 45% yield) as a white solid.

Preparation of ((2R,3S,5R)-2-((((1-adamantyl)methoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl isobutyrate



To a solution of 1-adamantylmethyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methyl carbonate (150 mg, 0.309 mmol, 1 eq) in pyridine (5 mL) was added 2-methylpropanoyl chloride (98.8 mg, 0.927 mmol, 3 eq) at 0° C. The resulting mixture was stirred at 0° C. for 0.5 h. The reaction mixture was quenched with ice water (20 mL) and exacted with ethyl acetate (30 mL). The organic layer was washed with H₂O (30 mL), brine (30 mL), dried over Na₂SO₄, and concentrated. The resulting residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluent of 0-1% MeOH/DCM @ 25 mL/min) to give the crude product. The crude product was further purified by prep-TLC (SiO₂, DCM:MeOH=10:1) to give the title compound (100 mg, 58% yield) as a white solid. LCMS (ESI) m/z, C₂₈H₃₄FN₅O₆: calculated 555.25, found (M+H)⁺: 556.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.99 (s, 1H), 6.36-6.33 (m, 3H), 5.73-5.69 (m, 1H), 4.42 (AB q, J=11.2 Hz, 2H), 3.72-3.64 (m, 2H), 3.08-3.06 (m, 1H), 3.01 (s, 1H), 2.66-2.62 (m, 2H), 1.95-1.93 (m, 3H), 1.79-1.71 (m, 3H), 1.71-1.59 (m, 3H), 1.50-1.49 (m, 6H), 1.22-1.18 (m, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.62 (s, 1F).

Example 21: ((2R,3S,5R)-2-(((3-(1-adamantyl)methoxy)carbonyl)oxy)methyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyltetrahydrofuran-3-yl isobutyrate (Compound 21)



153



To a solution of 3-(1-adamantyl)propyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydro-drofuran-2-yl]methyl carbonate (24 mg, 0.047 mmol, 1 eq) in pyridine (1 mL) was added 2-methylpropanoyl chloride (0.1 mL, 0.94 mmol, 20 eq) at 0° C. The resulting mixture was stirred at 0° C. for 1 h. The reaction mixture was quenched with water (10 mL) and diluted with EtOAc (40 mL). The organic layer was washed with H₂O (40 mL×3) and brine (40 mL), dried over Na₂SO₄ and concentrated. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX 80×30 mm×3 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 73%-100%, 9 min) to give the title compound (5.6 mg, 20.4% yield) as a white solid. LCMS (ESI) m/z, C₃₀H₃₈FN₅O₆: calculated 583.28, found (M+H)⁺: 584.3. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.98 (s, 1H), 6.37-6.32 (m, 3H), 5.72-5.69 (m, 1H), 4.49 (d, J=11.6 Hz, 1H), 4.33 (d, J=11.6 Hz, 1H), 4.04-3.96 (m, 2H), 3.11-3.05 (m, 1H), 3.01 (s, 1H), 2.68-2.60 (m, 2H), 1.91 (br s, 3H), 1.72-1.61 (m, 6H), 1.57-1.51 (m, 2H), 1.45 (d, J=2.4 Hz, 6H), 1.22-1.18 (m, 6H), 1.06-1.02 (m, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.62 (s, 1F).

Example 22: ((2R,3S,5R)-3-[3-(1-adamantyl)propoxycarbonyloxy]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-2-yl)methyl 3-(1-adamantyl)propyl carbonate

154


To a solution of 3-(1-adamantyl)propan-1-ol (28.0 mg, 0.144 mmol, 3 eq) and [(2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-2-[(4-nitrophenoxy)carbonyloxy-methyl]tetrahydrofuran-3-yl] (4-nitrophenyl) carbonate (30 mg, 0.048 mmol, 1 eq) in THF (2 mL) was added DMAP (5.88 mg, 0.048 mmol, 1 eq). The reaction mixture was stirred at 15° C. for 32 h was concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX 80×30 mm×3 um; mobile phase: [water (10 mM NH₄HCO₃) - ACN]; B %: 82%-100%, 9 min) to give the title compound (10.1 mg, 28.7% yield) as a white solid. LCMS (ESI) m/z, C₄₀H₅₂FN₅O₇; calculated 733.39, found (M+H)⁺: 734.4. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.71 (s, 1H), 6.28-6.05 (m, 3H), 5.37 (t, J=7.2 Hz, 1H), 4.27 (d, J=11.6 Hz, 1H), 4.07 (d, J=11.6 Hz, 1H), 3.91-3.86 (m, 2H), 3.75-3.73 (m, 2H), 2.88-2.86 (m, 1H), 2.78 (s, 1H), 2.48-2.46 (m, 1H), 1.69-1.67 (m, 6H), 1.44-1.38 (m, 12H), 1.24-1.19 (m, 16H), 0.87-0.80 (m, 4H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.49 (s, 1F).

Example 23: ((2R,3S,5R)-3-(1-adamantylmethoxy-carbonyloxy)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-2-yl)methyl 1-adamantylmethyl carbonate (Compound 23)




155

-continued




To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (35 mg, 0.119 mmol, 1 eq) in THF (5 mL) was added DMAP (29.2 mg, 0.239 mmol, 2 eq) and 1-adamantylmethyl (2,3,4,5,6-pentafluorophenyl) carbonate (404 mg, 1.07 mmol, 9 eq). The mixture was stirred at 15°C. for 40 h and was concentrated. The resulting residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluent of 0-4% i-PrOH/DCM @25 mL/min) to the title compound (72.8 mg, 90% yield) as a white solid. LCMS (ESI) m/z, C₃₆H₄₄FN₅O₇; calculated 677.32, found (M+H)⁺: 678.3. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.98 (s, 1H), 6.38-6.32 (m, 3H), 5.63 (t, J=5.6 Hz, 1H), 4.44 (d, J=11.6 Hz, 2H), 3.81 (d, J=11.6 Hz, 2H), 3.71-3.63 (m, 2H), 3.18-3.11 (m, 1H), 3.05 (s, 1H), 2.77-2.70 (m, 1H), 2.15-2.10 (m, 2H), 2.11-1.96 (m, 4H), 1.77-1.63 (m, 12H), 1.58-1.57 (m, 6H), 1.50-1.49 (m, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.49 (s, 1F).

Example 24: ((2R,3S,5R)-2-(1-adamantylmethoxy-carbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) ethyl carbonate (Compound 24)


**156**

-continued




To a solution of 1-adamantylmethyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydropyran-2-yl]methyl carbonate (15 mg, 0.031 mmol, 1 eq) in pyridine (2 mL) was added ethyl carbonochloride (0.07 mL, 0.74 mmol, 24 eq). The mixture was stirred at 0°C. for 2 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (30 mL). The organic layer was washed with brine (15 mL×3), dried over Na₂SO₄, and concentrated. The residue was purified by prep-HPLC (column: Welch Xtimate C18 150×25 mm×5 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 67%-97%, 9 min) to give the title compound (2.5 mg, 11% yield) as a white solid. LCMS (ESI) m/z, C₂₇H₃₂FN₅O₇; calculated 557.23, found (M+H)⁺: 558.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.72 (s, 1H), 6.13-6.07 (m, 3H), 5.40-5.37 (m, 1H), 4.28 (d, J=11.6 Hz, 1H), 4.10 (d, J=11.6 Hz, 1H), 4.00-3.96 (m, 2H), 3.46-3.38 (m, 2H), 2.90-2.88 (m, 1H), 2.80 (s, 1H), 2.50-2.48 (m, 1H), 1.69-1.68 (m, 3H), 1.46-1.41 (m, 3H), 1.38-1.24 (m, 3H), 1.26-1.21 (m, 6H), 1.05 (t, J=7.2 Hz, 3H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.51 (s, 1F).

Example 25: ((2R,3S,5R)-2-(1-adamantylmethoxy-carbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) ethyl carbonate (Compound 25)



157

-continued



15



To a solution of 4-(1-adamantyl)butyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydropyran-2-yl]methyl carbonate (20 mg, 0.038 mmol, 1 eq) in pyridine (2 mL) was added ethyl carbonochloride (0.20 mL, 2.09 mmol, 55 eq). The mixture was stirred at 0° C. for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed with brine (30 mL), dried over Na₂SO₄, and concentrated. The residue was purified by prep-HPLC (column: Welch Xtimate C18 150×25 mm×5 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 70%-100%, 9 min) to give the title compound (4.8 mg, 21% yield) as a white solid. LCMS (ESI) m/z, C₃₀H₃₈FN₅O₇: calculated 599.28, found (M+H)⁺: 600.3. ¹H NMR (400 MHz, CD₃CN) δ

20

(ppm) 7.73 (s, 1H), 6.12 (br s, 1H), 6.11-6.07 (m, 2H), 5.41-5.38 (m, 1H), 4.30 (d, J=11.6 Hz, 1H), 4.10 (d, J=11.6 Hz, 1H), 4.09-3.98 (m, 2H), 3.82-3.78 (m, 2H), 2.92-2.89 (m, 1H), 2.81 (s, 1H), 2.50-2.46 (m, 1H), 1.72 (s, 3H), 1.48-1.45 (m, 3H), 1.40-1.37 (m, 3H), 1.32-1.25 (m, 2H), 1.22-1.21 (d, J=2.4 Hz, 6H), 1.8-1.04 (m, 3H), 1.03-0.97 (m, 2H), 0.81-0.77 (m, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.55 (s, 1F).

25


Example 26: ((2R,3S,5R)-2-[3-(1-adamantyl)propoxycarbonyloxymethyl]-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydropyran-3-yl) ethyl carbonate (Compound 26)



159

To a solution of 3-(1-adamantyl)propyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methyl carbonate (20 mg, 0.039 mmol, 1 eq) in pyridine (2 mL) was added ethyl carbonochloride (0.07 mL, 0.74 mmol, 19 eq). The mixture was stirred at 0° C. for 1 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (30 mL). The organic layer was washed with brine (15 mL), dried over Na₂SO₄ and concentrated. The residue was purified by prep-HPLC (column: Welch Xtimate C18 150×25 mm×5 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 67%-97%, 9 min) to give the title compound (1.3 mg, 5.7% yield) as a white solid. LCMS (ESI) m/z, C₂₉H₃₆FN₅O₇; calculated 585.26, found (M+H)⁺: 586.3. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.74 (s, 1H), 6.10 (t, J=6.4 Hz, 3H), 5.40 (t, J=7.2 Hz, 1H), 4.31 (d, J=11.2 Hz, 1H), 4.15-4.07 (d, J=11.2 Hz, 1H), 4.05-3.95 (m, 2H), 3.85-3.70 (m, 2H), 2.94-2.90 (m, 1H), 2.82 (s, 1H), 2.53-2.45 (m, 1H), 1.70-1.68 (m, 3H), 1.53-1.45 (m, 3H), 1.44-1.37 (m, 3H), 1.36-1.26 (m, 2H), 1.27-1.20 (m, 6H), 1.07 (t, J=7.2 Hz, 3H), 0.84-0.79 (m, 2H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.54 (s, 1F).

Example 27: 1-adamantyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-3-ethoxycarbonyloxy-2-ethynyl-tetrahydrofuran-2-yl)methyl carbonate (Compound 27)





To a solution of 1-adamantyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methyl carbonate (15 mg, 0.032 mmol, 1 eq) in pyridine (1 mL) was added ethyl carbonochloride (0.175 mL, 1.86 mmol, 58 eq). The mixture was stirred at 0° C. for 2 h. The reaction mixture was quenched by water (5 mL) at 0° C., and then diluted with DCM (10 mL) and extracted with DCM (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by prep-HPLC (column: Welch Xtimate C18 150×25 mm×5 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 66%-99%, 9 min) to give the title compound (2.6 mg, 15.0% yield) as a white solid. LCMS (ESI) m/z, C₂₇H₃₂FN₅O₆; calculated 541.23, found (M+H)⁺: 542.0. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.98 (s, 1H), 6.37-6.29 (m, 3H), 5.74-5.71 (m, 1H), 4.47 (d, J=12.0 Hz, 1H), 4.21 (d, J=11.6 Hz, 1H), 3.13-3.06 (m, 1H), 3.01 (s, 1H), 2.68-2.60 (m, 2H), 2.13-2.09 (m, 6H), 2.01-1.96 (m, 3H), 1.64 (br s, 6H), 1.22-1.18 (m, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.58 (s, 1F).

160

mM NH₄HCO₃)-ACN]; B %: 57%-87%, 9 min) to give the title compound (5.0 mg, 28.67% yield) as a white solid. LCMS (ESI) m/z, C₂₆H₃₀FN₅O₇; calculated 543.21, found (M+H)⁺: 544.0. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.96 (s, 1H), 6.36-6.29 (m, 3H), 5.67-5.63 (m, 1H), 4.51 (d, J=11.6 Hz, 1H), 4.26-4.20 (m, 3H), 3.19-3.12 (m, 1H), 3.03 (s, 1H), 2.75-2.68 (m, 1H), 2.14-2.11 (m, 5H), 1.95-1.93 (m, 2H), 1.90-1.88 (m, 2H), 1.64 (s, 6H), 1.32-1.27 (m, 3H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.48 (s, 1F).




Example 28: ((2R,3S,5R)-2-(1-adamantyloxycarbonyloxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-tetrahydrofuran-3-yl) 2-methylpropanoate (Compound 28)



To a solution of 1-adamantyl [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methyl carbonate (15 mg, 0.032 mmol, 1 eq) in pyridine (1 mL) was added 2-methylpropanoyl chloride (0.2 mL, 1.92 mmol, 60 eq). The mixture was stirred at 0° C. for 1 h. The resulting mixture was diluted with EtOAc (30 mL), then washed with H₂O (20 mL×2), brine (20 mL), dried over Na₂SO₄, and concentrated. The residue was purified by prep-HPLC (column: Welch Xtimate C18 150×25 mm×5 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 66%-99%, 9 min) to give the title compound (2.6 mg, 15.0% yield) as a white solid. LCMS (ESI) m/z, C₂₇H₃₂FN₅O₆; calculated 541.23, found (M+H)⁺: 542.0. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.98 (s, 1H), 6.37-6.29 (m, 3H), 5.74-5.71 (m, 1H), 4.47 (d, J=12.0 Hz, 1H), 4.21 (d, J=11.6 Hz, 1H), 3.13-3.06 (m, 1H), 3.01 (s, 1H), 2.68-2.60 (m, 2H), 2.13-2.09 (m, 6H), 2.01-1.96 (m, 3H), 1.64 (br s, 6H), 1.22-1.18 (m, 6H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.58 (s, 1F).


161

Example 29: (1*R*,13*R*,15*R*)-15-(6-amino-2-fluoro-9*H*-purin-9-yl)-13-ethynyl-2,9,11,14-tetraoxabicyclo[11.3.0]hexadecane-3,10-dione (Compound 29)

**162**


Preparation of tert-butyl 6-[[(2*R*,3*S*,5*R*)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl]methoxycarbonyloxy]hexanoate

50




163

-continued




To a solution of [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methoxycarbonyloxyhexanoate (150 mg, 0.327 mmol, 1 eq) in THE (10 mL) was added DMAP (4.03 mg, 0.033 mmol, 0.1 eq) and tert-butyl 6-hydroxyhexanoate (185 mg, 0.982 mmol, 3 eq). The mixture was stirred at 15° C. for 16 h and then was concentrated. The resulting residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, eluent of 0-3% MeOH/DCM @22 mL/min) to give tert-butyl 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methoxycarbonyloxyhexanoate (60 mg, 36% yield) as a light yellow gum.

Preparation of 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methoxycarbonyloxyhexanoic acid




To a solution of tert-butyl 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methoxycarbonyloxyhexanoate (90 mg, 0.177 mmol, 1 eq) in DCM (5 mL) was added TFA (1 mL). The mixture was

164



stirred at 15° C. for 16 h and then was concentrated. The resulting residue was purified by prep-TLC (SiO₂, DCM: MeOH=10:1) to give 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methoxycarbonyloxyhexanoic acid (40 mg, 50% yield) as a yellow gum.

Preparation of (1R,13R,15R)-15-(6-amino-2-fluoro-purin-9-yl)-13-ethynyl-2,9,11,14-tetraoxabicyclo[11.3.0]hexadecane-3,10-dione




To a solution of 6-[(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-3-hydroxy-tetrahydrofuran-2-yl]methoxycarbonyloxyhexanoic acid (40 mg, 0.089 mmol, 1 eq) in MeCN (3 mL) and DCM (3 mL) was added TCFH (69.9 mg, 0.248 mmol, 2.8 eq) and 1-methylimidazole (24.1 mg, 0.292 mmol, 3.3 eq). The mixture was stirred at 15° C. for 40 h and then was concentrated. The resulting residue was purified by prep-HPLC (NH₄HCO₃ condition; column: Phenomenex Gemini-NX 80×30 mm×3 um; mobile phase: [water (10 mM NH₄HCO₃)-ACN]; B %: 31%-61%, 9 min) to give the title compound (2.3 mg, 6.0% yield) as a white solid. LCMS (ESI) m/z, C₁₉H₂₀FN₅O₆: calculated 433.14,


165

found $(M+H)^+$: 434.1. ^1H NMR (400 MHz, CD_3CN) δ (ppm) 7.95 (s, 1H), 6.33-6.31 (m, 3H), 5.83-5.79 (m, 1H), 4.76 (d, $J=10.8$ Hz, 1H), 4.58-4.57 (m, 1H), 4.16 (d, $J=11.2$ Hz, 1H), 4.07-4.05 (m, 1H), 3.08-3.04 (m, 2H), 2.61-2.51 (m, 1H), 2.50-2.35 (m, 1H), 2.24-2.19 (m, 1H), 1.75-1.65 (m, 4H), 1.68-1.52 (m, 1H), 1.47-1.29 (m, 1H). ^{19}F NMR (376 MHz, CD_3CN) δ (ppm) -52.44 (s, 1F).


Example 30: (6R,8R,10R)-8-(6-amino-2-fluoro-9H-purin-9-yl)-10-ethynyl-3,5,9,12,14-pentaoxatricyclo [14.4.0.0,6,10]icosane-4,13-dione (Compound 30)



Preparation of [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-[(2,3,4,5,6-pentafluorophenoxy)carbonyloxymethyl]tetrahydrofuran-3-yl] (2,3,4,5,6-pentafluorophenyl) carbonate



**166**

-continued



To a solution of (2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol (100 mg, 0.341 mmol, 1 eq) in THE (10 mL) was added DMAP (8.3 mg, 0.068 mmol, 0.2 eq) and bis(2,3,4,5,6-pentafluorophenyl) carbonate (282 mg, 0.716 mmol, 2.1 eq). The mixture was stirred at 10° C. for 6 h and then was concentrated. The residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0-5% MeOH/DCM gradient @ 50 mL/min) to give [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-[(2,3,4,5,6-pentafluorophenoxy)carbonyloxymethyl]tetrahydrofuran-3-yl] (2,3,4,5,6-pentafluorophenyl) carbonate (80 mg, 32.9% yield) as a white solid.

Preparation of (6R,8R,10R)-8-(6-amino-2-fluoro-purin-9-yl)-10-ethynyl-3,5,9,12,14-pentaoxatricyclo [14.4.0.0,6,10]icosane-4,13-dione



To a solution of [(2R,3S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-[(2,3,4,5,6-pentafluorophenoxy)carbonyloxymethyl]tetrahydrofuran-3-yl] (2,3,4,5,6-pentafluorophenyl) carbonate (80 mg, 0.112 mmol, 1 eq) in THE (12 mL) was added DMAP (13.7 mg, 0.112 mmol, 1 eq) and [(1R,2S)-2-(hydroxymethyl)cyclohexyl]methanol (16.2 mg,

167

0.112 mmol, 1 eq). The mixture was stirred at 10° C. for 44 h and then was concentrated. The residue was purified by prep-TLC (SiO₂, DCM:MeOH=10:1) to give (6R,8R,10R)-8-(6-amino-2-fluoro-purin-9-yl)-10-ethynyl-3,5,9,12,14-pentaoxatricyclo[14.4.0.0.6,10]icosane-4,13-dione (2.8 mg, 5.1% yield) as a white solid. LCMS (ESI) m/z, C₂₂H₂₄FN₅O₇; calculated 489.17, found (M+H)⁺: 490.2. ¹H NMR (400 MHz, CD₃CN) δ (ppm) 7.95 (d, J=9.6 Hz, 1H), 6.36-6.31 (m, 2H), 6.14-6.10 (m, 0.5H), 5.63-5.61 (m, 0.5H), 4.78 (d, J=11.2 Hz, 0.5H), 4.57-4.37 (m, 2.5H), 4.22-4.15 (m, 2H), 4.01-3.91 (m, 1H), 3.25-3.17 (m, 0.5H), 3.03 (d, J=3.2 Hz, 1H), 2.98-2.91 (m, 0.5H), 2.82-2.74 (m, 0.5H), 2.67-2.61 (m, 0.5H), 2.47 (br s, 0.5H), 2.21 (br s, 0.5H), 1.78-1.57 (m, 2.5H), 1.54-1.23 (m, 7.5H). ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm) -52.45 (s, 1F).

Example 31: Conversion and Stability of the Adenosine Derivative Prodrugs

Stability of prodrugs and conversion of the prodrugs to the parent EFdA (formula T-1A) were measured in both plasma and liver S9 assays and the data are shown in Table 2.

Plasma Stability

The pooled frozen plasma was thawed in a water bath at 37° C. prior to experiment. Plasma was centrifuged at 4000 rpm for 5 min and the clots were removed if any. The pH will be adjusted to 7.4±0.1 if required.

Preparation of test compounds and positive control (propantheline bromide): 1 mM intermediate solution was prepared by diluting 10 μL of the stock solution with 90 μL MeOH; 1 mM intermediate of positive control Propantheline was prepared by diluting 10 μL of the stock solution with 90 μL ultrapure water. 100 μM dosing solution was prepared by diluting 20 μL of the intermediate solution (1 mM) with 180 μL MeOH. 98 μL of blank plasma was spiked with 2 μL of dosing solution (100 μM) to achieve 2 μM of the final concentration in duplicate and samples were incubated at 37° C. in a water bath. At each time point (0, 10, 30, 60 and 120 min), 400 μL of stop solution (0.1% FA in MeOH containing 200 ng/mL tolbutamide and 200 ng/mL Labetalol) was added to precipitate protein and mixed thoroughly. Centrifuged sample plates at 4,000 rpm for 10 min. An aliquot of supernatant (100 μL) was transferred from each well to another plates. Data analysis: The % remaining of test compound after incubation in plasma was calculated using following equation:

$$\% \text{ Remaining} = 100 \times (\text{PAR at appointed incubation time} / \text{PAR at } T_0 \text{ time})$$

where PAR is the peak area ratio of analyte versus internal standard (IS) (LC/MS/MS mobile phase condition: 0.1% Formic Acid in Water/0.1% Formic Acid in Acetonitrile. The appointed incubation time points are T0 (0 min), Tn (n=0, 10, 30, 60, 120 min).

Liver S9 Stability

Intermediate solution: Dilute 5 μL of compounds or controls (7-ethoxycoumarin) from stock solution (10 mM) with 495 μL MeOH (Conc.: 100 μM, 1% DMSO, 99% MeOH). Stop solution: Cold ACN (including 100 ng/mL Tolbutamide and Labetalol as internal standard). Add 2 μL test compound or control working solution/well to all plates (T0, T5, T10, T20, T30, T60, NCF60) except matrix blank. Add 600 μL/well stop solution (cold in 4° C., including 100 ng/mL Tolbutamide/100 ng/mL Labetalol) to terminate the T0 plate, then put it on ice. Dispense 840 μL/well S9 solution to 96-well plate as reservoir according to plate map.

168

Then add 100 μL/well to every plate by Apricot. Incubate S9 solution and compound at 37° C. for about 10 min except NCF60 and T0. After adding S9 solution and 98 μL LPB buffer to NCF60, incubate at 37° C. without pre-warming, start timer 1. After 60 min, add 600 μL/well stop solution to terminate the reaction. After pre-warming, dispense 760 μL/well cofactor solution to 96-well plate as reservoir according to plate map. Then add 98 μL/well to every plate by Apricot to start reaction. Incubate at 37° C., start timer 2. Add 600 μL/well stop solution (cold in 4° C., including 100 ng/mL Tolbutamide and Labetalol) to terminate the reaction. Samples are centrifuged at 4000 rpm for 20 min. While centrifuging, load 8×new 96-well plate with 300 μL HPLC water, then transfer 100 μL supernatant, mix with water for LC/MS/MS, transferred to Bioanalytical Services for LC-MS/MS analysis. Use equation of first order kinetics to calculate t_{1/2} and CL: Equation of first order kinetics:

$$C_t = C_0 \cdot e^{-k_e \cdot t}$$

$$C_t = \frac{1}{2} C_0, T_{1/2} = \frac{\ln 2}{-k_e} = \frac{0.693}{-k_e}$$

$$CL_{int(S9)} = Vd \cdot k_e$$

$$Vd = 1 \text{ mL/mg}$$

The stability results of exemplary compounds in human plasma and human liver S9 were listed in Table 2 below.

TABLE 2

Compound	Conversion and Half Life Data.			
	Stability in Human Plasma Half-life	Formation of EFdA at 30 min	Stability in Human Liver S9 Half-life	Formation of EFdA at 30 min
1	A	No	C	Yes
2	B	Yes	C	Yes
3	C	No	C	Yes
4	A	Yes	C	Yes
6	A	No	C	Yes
7	C	Yes	C	Yes
8	B	Yes	C	Yes
9	A	No	C	Yes
10	C	Yes	C	Yes
11	NA	NA	C	Yes
12	C	Yes	C	Yes
13	NA	NA	C	Yes
14	C	Yes	C	Yes
15	C	Yes	C	Yes
16	B	Yes	NA	NA
17	A	Yes	C	Yes
18	C	No	C	Yes
19	C	No	C	Yes
20	B	No	C	Yes
21	B	Yes	C	Yes
22	A	No	B	Yes
23	A	No	C	Yes
24	B	Yes	C	Yes
25	B	Yes	C	Yes
26	C	Yes	C	Yes
27	A	No	C	Yes
28	A	No	C	Yes
29	C	Yes	C	Yes
30	B	No	C	Yes

Half-life ranges: A: >200 minutes; B: 50-200 minutes; C: <50 minutes; NA: not tested.

169

Example 32: Plasma Exposures Following Intramuscular Administration of Prodrugs to Cynomolgus Monkeys

The pharmacokinetics of EFdA and Compound 2, 7, 10 and 12 were studied in cynomolgus monkeys after a single intramuscular (IM) administration of 10 mg/kg.

Formulations: The prodrugs were formulated as homogeneous opaque suspensions at 100 mg/ml, in 20% PEG400, 10% solutol, and 88% water within 0.5 hour prior to dose.

Dose Administration and Sample Collection: The in-life phase of this study was conducted at the WuXi AppTec (Suzhou) Co., Ltd, Suzhou, China in accordance with the WuXi Institutional Animal Care and Use Committee (IA-CUC) standard animal procedures along with the IACUC guidelines that are in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and was approved by the IACUA Committee. Non-naïve male cynomolgus monkey (3+-1 kg) were used for the studies. Each drug was administered as a single dose of 10 mg/kg by intramuscular injection (0.1 ml/kg). Plasma samples were collected at 0 (pre-dose), 15 and 30 min, 1, 2, 4, 7, 12, 24, 48, 72, 96, 120, 144 and 168 h post-dose. Blood (approximately 0.9 mL) was processed immediately for plasma by centrifugation at 3,500 rpm at 5° C. for 10 min immediately after collection using commercially available ice-cold K₂EDTA tubes pre-aliquoted with concentrated

170

scopic mode using unit resolution mode. Multiple reaction monitoring (MRM) modes were used to quantify both prodrugs and EFdA. Peak areas were integrated by the Sciex program Analyst®, version 1.6.3 where concentrations were determined by a weighted (1/ \times 2) linear regression of peak area ratios (peak area of EFdA/peak area of corresponding IS) versus the nominal concentrations of the plasma calibration standards. Calculations were performed on unrounded numbers. Overall, Analyst® determined the precision and accuracy for the calibration standards and QC samples.

Pharmacokinetic Calculations: The noncompartmental (NCA) analysis of EFdA and prodrug individual plasma concentration-time data were conducted using WinNonlin module in the Phoenix PK/PD Platform (Certara Inc., Princeton, NJ 08540). Calculations were performed prior to rounding and nominal sampling times were used in the pharmacokinetic analysis. Exposures were expressed as areas under concentration curves in plasma from zero to 168 hours ($AUC_{0-168\text{ hr}}$). The AUC values were calculated using the linear trapezoidal rule.

Plasma Concentrations: The results of the PK studies are shown in Table 3 and FIGS. 1-4. These data establish in vivo that Compound 2, 7, 10 and 12 can be readily delivered intramuscularly, and can efficiently release EFdA in vivo with minimal to low levels of prodrug detected in the systemic circulation.

TABLE 3

EFdA and compound 2, 7, 10 and 12 exposures in plasma after a single intramuscular injection of compound 2, 7, 10 and 12 to Cynomolgus monkeys

Compound administered	Dose (mg/kg)	Compound	PK Parameters		
			$AUC_{0-168\text{ hr}}$ (ng*hr/mL)	T_{max} (hr)	C_{max} (ng/mL)
2	10	Compound 2	27.3	0.917	5.23
		EFdA	6408	12.7	142
7	10	Compound 7	232	0.417	44.6
		EFdA	5859	1.00	127
10	10	Compound 10	34.1	1.00	7.25
		EFdA	900	3.33	6.95
12	10	Compound 12	813	0.583	79.6
		EFdA	5252	1.33	121


cocktail blood stabilizer (1:9 ratio). Plasma samples were frozen and maintained at -70° C. until analyzed.

Determination of EFdA and Prodrugs in plasma: Briefly, plasma (20 μ L) was mixed with 200 μ L acetonitrile containing internal standards to precipitate protein. Consistent with sample collection procedure, the same cocktail protocol was also added to stabilize the prodrug in the standard and QC samples.

Bioanalysis: A Sciex API-6500 plus triplequadrupole mass spectrometer coupled with a Waters ACQUITY UPLC system (Milford, MA) was used for quantitative analysis of plasma samples. The column was a Waters HSS T3 column (2.1 \times 50 mm, 1.8 mm). The mobile phases used were: A, 0.1% formic acid in water; B, 0.1% formic acid in acetonitrile. The flow rate was 0.6 mL/min with a total run time of 2.0 min. The UPLC gradient was initiated at 95% A/5% B, followed by linear gradient increase to 30% B over the next 0.7 min; the gradient was subsequently increased to 98% of mobile B over the next 0.5 min and then held for additional 0.6 min before ramping down to 5% mobile phase B within the following 0.2 min. Detection of the prodrug and EFdA were achieved using positive ion electrospray mass spectro-

45 The invention claimed is:

1. An adenosine derivative having a structure of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-


171

G-(C₁₋₁₀alkylene)-J-, —(CO)-G-(C₂₋₁₀alkenylene)-J-, and —(CO)-G-(C₂₋₁₀alkynylene)-J-; wherein:

G is selected from the group consisting of a bond, O, NH, and S;

J is selected from the group consisting of a bond, O, NH, S, —(CO)-G-;

R¹ is



wherein R⁴ is H, C₁₋₅alkyl, C₁₋₅haloalkyl, or C₁₋₅alkoxy;

R² is selected from the group consisting of H, C₁₋₂₀alkyl, C₁₋₂₀haloalkyl, C₁₋₂₀alkoxy, C₂₋₂₀alkenyl, C₂₋₂₀alkynyl, C₃₋₂₀cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and

R³ is selected from the group consisting of H, —(CO)-G-C₁₋₁₀alkyl, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.

2. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein A is selected from the group consisting of a bond, —(CO)—, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-.

3. The adenosine derivative or pharmaceutically acceptable salt of claim 2, wherein A is a bond or —(CO)-G-(C₁₋₅alkylene)-J-.

4. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein E is a bond, —(CO)-G-, and —(CO)-G-(C₁₋₅alkylene)-J-.


5. The adenosine derivative or pharmaceutically acceptable salt of claim 4, wherein E is a bond or —(CO)-G-(C₁₋₅alkylene)-J-.

6. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein G is a bond or O.

7. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein J is a bond or O.

8. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein G is O and J is a bond.


9. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein R² is H, C₁₋₅alkyl, or



wherein R⁴ is H, C₁₋₅alkyl, C₁₋₅haloalkyl, or C₁₋₅alkoxy.

10. The adenosine derivative or pharmaceutically acceptable salt of claim 9, wherein R⁴ is H.

11. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein R² is

172




wherein R⁴ is H.

12. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein R² is H.

13. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein R³ is H, —(CO)—C₁₋₅alkyl, —(CO)—O—C₁₋₅alkyl, or C₁₋₅alkyl.


14. The adenosine derivative or pharmaceutically acceptable salt of claim 13, wherein R³ is H.

15. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein said adenosine derivative is selected from the group consisting of:




173

-continued



or a pharmaceutically acceptable salt thereof.

16. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein said adenosine derivative is selected from the group consisting of:

174

17. The adenosine derivative or pharmaceutically acceptable salt of claim 1, wherein said adenosine derivative is a reverse transcriptase inhibitor activity in vivo, a reverse transcriptase chain terminator activity in vivo, DNA translocation inhibitor activity in vivo, or a combination thereof.

18. A pharmaceutical composition comprising the adenosine derivative or pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier.

19. A method for treating an HIV infection, comprising administering a subject in need thereof an effective dosage of the pharmaceutical composition of claim 18.

* * * * *